WO2022138735A1 - 悪性腫瘍疾患の改善用医薬組成物 - Google Patents
悪性腫瘍疾患の改善用医薬組成物 Download PDFInfo
- Publication number
- WO2022138735A1 WO2022138735A1 PCT/JP2021/047614 JP2021047614W WO2022138735A1 WO 2022138735 A1 WO2022138735 A1 WO 2022138735A1 JP 2021047614 W JP2021047614 W JP 2021047614W WO 2022138735 A1 WO2022138735 A1 WO 2022138735A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration group
- formula
- compound
- cancer
- lymphoma
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- 230000003211 malignant effect Effects 0.000 title claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 27
- 201000010099 disease Diseases 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 246
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 261
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 103
- 208000034578 Multiple myelomas Diseases 0.000 claims description 89
- 206010025323 Lymphomas Diseases 0.000 claims description 79
- 229960004641 rituximab Drugs 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 208000024891 symptom Diseases 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- 108700012434 CCL3 Proteins 0.000 claims description 29
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 29
- 108090001005 Interleukin-6 Proteins 0.000 claims description 27
- 230000001939 inductive effect Effects 0.000 claims description 27
- 206010061728 Bone lesion Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- 230000004663 cell proliferation Effects 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 18
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 208000017169 kidney disease Diseases 0.000 claims description 16
- 235000021067 refined food Nutrition 0.000 claims description 16
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 15
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 14
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 14
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 14
- 230000012010 growth Effects 0.000 claims description 14
- 230000000148 hypercalcaemia Effects 0.000 claims description 14
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 14
- 230000002093 peripheral effect Effects 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 13
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims description 12
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 206010038389 Renal cancer Diseases 0.000 claims description 12
- 201000010982 kidney cancer Diseases 0.000 claims description 12
- 201000007270 liver cancer Diseases 0.000 claims description 12
- 208000014018 liver neoplasm Diseases 0.000 claims description 12
- 208000017604 Hodgkin disease Diseases 0.000 claims description 11
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 11
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 11
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 11
- 201000011549 stomach cancer Diseases 0.000 claims description 11
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 10
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims description 10
- 208000032612 Glial tumor Diseases 0.000 claims description 10
- 206010018338 Glioma Diseases 0.000 claims description 10
- 201000003791 MALT lymphoma Diseases 0.000 claims description 10
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 10
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 206010002022 amyloidosis Diseases 0.000 claims description 9
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 8
- 229960001467 bortezomib Drugs 0.000 claims description 8
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 7
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 7
- 229960003347 obinutuzumab Drugs 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 3
- 230000009036 growth inhibition Effects 0.000 claims 1
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 abstract description 59
- 230000000694 effects Effects 0.000 abstract description 42
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 abstract description 41
- 229940043357 mangiferin Drugs 0.000 abstract description 35
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract description 15
- 230000001976 improved effect Effects 0.000 abstract description 7
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 3
- 102000020233 phosphotransferase Human genes 0.000 abstract description 3
- 230000037406 food intake Effects 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 88
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 79
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 55
- 230000030833 cell death Effects 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 230000003833 cell viability Effects 0.000 description 49
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 46
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 46
- 229910002091 carbon monoxide Inorganic materials 0.000 description 40
- 238000000034 method Methods 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 31
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 30
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 29
- 230000004913 activation Effects 0.000 description 27
- 238000004519 manufacturing process Methods 0.000 description 27
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 26
- 102000004889 Interleukin-6 Human genes 0.000 description 25
- 102000003945 NF-kappa B Human genes 0.000 description 25
- 108010057466 NF-kappa B Proteins 0.000 description 25
- 229940100601 interleukin-6 Drugs 0.000 description 25
- 230000028327 secretion Effects 0.000 description 25
- 230000004614 tumor growth Effects 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 22
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 230000006698 induction Effects 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000013641 positive control Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 230000037361 pathway Effects 0.000 description 18
- 238000007906 compression Methods 0.000 description 17
- 230000006835 compression Effects 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 206010041541 Spinal compression fracture Diseases 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 238000012258 culturing Methods 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 14
- 201000000050 myeloid neoplasm Diseases 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 229930182555 Penicillin Natural products 0.000 description 13
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- 238000010899 nucleation Methods 0.000 description 13
- 229940049954 penicillin Drugs 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 13
- 229960005322 streptomycin Drugs 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- SGQWQUYTTYVSBS-UHFFFAOYSA-N 1,3,6,7-tetramethoxyxanthen-9-one Chemical compound COC1=C(OC)C=C2C(=O)C3=C(OC)C=C(OC)C=C3OC2=C1 SGQWQUYTTYVSBS-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010060860 Neurological symptom Diseases 0.000 description 9
- 208000005250 Spontaneous Fractures Diseases 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 8
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 239000004055 small Interfering RNA Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010038357 Renal amyloidosis Diseases 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 201000007891 familial visceral amyloidosis Diseases 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
- 102000006835 Lamins Human genes 0.000 description 6
- 108010047294 Lamins Proteins 0.000 description 6
- 101710085938 Matrix protein Proteins 0.000 description 6
- 101710127721 Membrane protein Proteins 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 210000005053 lamin Anatomy 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- -1 xanthone compound Chemical class 0.000 description 6
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 5
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 5
- 108010014632 NF-kappa B kinase Proteins 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone powder Natural products C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 5
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- KVZUCOGWKYOPID-UHFFFAOYSA-N 2,4,5-Trimethoxybenzoic acid Chemical compound COC1=CC(OC)=C(C(O)=O)C=C1OC KVZUCOGWKYOPID-UHFFFAOYSA-N 0.000 description 4
- JEPXZNXBEFYVOZ-UHFFFAOYSA-N 2,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(OC)=C(C(Cl)=O)C=C1OC JEPXZNXBEFYVOZ-UHFFFAOYSA-N 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 208000007452 Plasmacytoma Diseases 0.000 description 4
- 206010041549 Spinal cord compression Diseases 0.000 description 4
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 4
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 241000522213 Dichilus lebeckioides Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000005747 Transcription Factor RelA Human genes 0.000 description 3
- 108010031154 Transcription Factor RelA Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006552 constitutive activation Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010034156 Pathological fracture Diseases 0.000 description 2
- 208000033014 Plasma cell tumor Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical group CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 235000019543 dairy drink Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- BWODNRWGBLRZJI-UHFFFAOYSA-N (2,3,4,5,6-pentamethoxyphenyl)-phenylmethanone Chemical compound COC1=C(OC)C(OC)=C(OC)C(OC)=C1C(=O)C1=CC=CC=C1 BWODNRWGBLRZJI-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KWHQKWXWZCCKJJ-UHFFFAOYSA-N 1-hydroxy-3,6,7-tris(methoxymethoxy)xanthen-9-one Chemical compound OC1=CC(=CC=2OC3=CC(=C(C=C3C(C1=2)=O)OCOC)OCOC)OCOC KWHQKWXWZCCKJJ-UHFFFAOYSA-N 0.000 description 1
- ZTGSICGSZVMZDH-UHFFFAOYSA-N 4-[1-(2-amino-5-chloropyrimidin-4-yl)-2,3-dihydroindol-6-yl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)but-3-yn-2-ol Chemical compound CC1=NOC(C(C)(O)C#CC=2C=C3N(CCC3=CC=2)C=2C(=CN=C(N)N=2)Cl)=N1 ZTGSICGSZVMZDH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 206010056663 Gastric infection Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 description 1
- 101000978570 Homo sapiens Noelin Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 102100023731 Noelin Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- BMZWBEHLBROZOP-UHFFFAOYSA-N c1n[nH]cc1-c1c[nH]c2cnccc12 Chemical class c1n[nH]cc1-c1c[nH]c2cnccc12 BMZWBEHLBROZOP-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 108091070778 miR-520e stem-loop Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical group CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D311/86—Oxygen atoms, e.g. xanthones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Definitions
- the present invention relates to a compound that inhibits an NF- ⁇ B-induced kinase (also known as NIK-MAP3K14) useful for the treatment and / or prevention of malignant tumors such as malignant lymphoma and multiple myeloma.
- the present invention also relates to a composition, a pharmaceutical composition, and a processed food for the prevention / treatment of malignant tumors such as malignant lymphoma and multiple myeloma using the compound.
- NF- ⁇ B Nuclear factor kappa B
- This NF- ⁇ B has five members: NF- ⁇ Bp65 (p65), RelB, c-Rel, NF- ⁇ B1 (which is present in both precursor p105 and truncated p50) and NF- ⁇ B2 (which is It is composed of both precursor p100 and truncated p52).
- NF- ⁇ B1 cut type p50; NF- ⁇ Bp50
- NF- ⁇ B2 cut type p52; NF- ⁇ Bp52
- RelB form a heterodimer
- NF- ⁇ B heterodimers activation of these NF- ⁇ B heterodimers is carried out by a signal transduction pathway strictly controlled by continuous events including phosphorylation reaction and proteolysis.
- This signal transduction route is classified into two routes, a classical route (Canonical route) and a non-classical route (Non-canonical route).
- NIK is a serine / threonine kinase and plays a role in both pathways. NIK is essential in non-classical signaling pathways and phosphorylates IKK ⁇ to partially degrade NF- ⁇ Bp100 and release NF- ⁇ Bp52.
- NF- ⁇ Bp52 forms a heterodimer with RelB, translocates into the nucleus, and expresses the gene.
- the classical pathway activates the IKK ⁇ , IKK ⁇ and IKK ⁇ complexes to form heterodimers of p65 and NF- ⁇ Bp50. Gene expression is regulated by the translocation of this heterodimer into the nucleus.
- NIK is activated by ligands such as B cell activating factor (BAFF), CD40 ligand and tumor necrosis factor ⁇ (TNF ⁇ ). It is known that NIK is important for the activation of signal transduction pathways by these ligands. Due to its important role, NIK expression is tightly regulated.
- BAFF B cell activating factor
- TNF ⁇ tumor necrosis factor ⁇
- Non-Patent Document 1 Under normal non-stimulation conditions, the amount of NIK protein in the cell is small because NIK is degraded by the interaction between the ubiquitin ligase TNF receptor-related factor (TRAF) and NIK. It is believed that when the non-classical pathway is stimulated by the ligand, activated receptors dissociate the TRAF-NIK complex, thereby increasing NIK concentration. (Non-Patent Document 1).
- BAFF is produced and secreted from T cells, monocytes / macrophages, dendritic cells, etc., and is known to control B cell differentiation, activation, survival, etc. via three types of receptors on B cells.
- Non-Patent Document 2 Non-Patent Document 2.
- BAFF receptors include BAFF-R (BAFF-Receptor), TACI (Transmenbrane activator and calcium modulator and cyclophilin ligand interactor), and BCMA (B cellment).
- BAFF-R and BCMA are mainly expressed on B cells, and TACI is expressed on B cells and activated T cells.
- the interaction of BAFF with BAFF-R activates the NIK-mediated non-classical NF- ⁇ B signaling pathway.
- Non-Patent Documents 3 and 4 It has been shown that the NF- ⁇ B pathway is constitutively activated in multiple myeloma (Non-Patent Documents 3 and 4). In addition, it has been shown that in patients with multiple myeloma, amplification of the NIK gene, deletion of the TRAF gene, and point mutation of the TRAF gene are observed, which increases the expression level of NIK protein and constitutively activates NIK. It is a factor that activates the NF- ⁇ B pathway. In addition, it has been shown that inhibition of NIK with shRNA (NIK shRNA) suppresses NF- ⁇ B activation and induces cell death in multiple myeloma cell lines (Non-Patent Document 3).
- NIK shRNA inhibition of NIK with shRNA
- Non-Patent Documents 5 and 6 It has also been shown that in patients with multiple myeloma, the concentration of BAFF in the serum is elevated, and BAFF is secreted not only from monocytes and macrophages but also from multiple myeloma cells, and BAFF. It has been reported that autocline enhances the proliferation of multiple myeloma cells.
- Non-Patent Document 7 It has been shown that point mutations in the TRAF gene and an increase in the expression level of NIK protein are also observed in patients with Hodgkin lymphoma, and it has been reported that NIK shRNA induces cell death in these cases as well (Non-Patent Document 7). ..
- Non-Patent Document 8 the cell mass of NIK protein also increases in adult T-cell leukemia cells, and that NIK shRNA treatment suppresses tumor growth of adult T-cell leukemia in vivo.
- API2-MALT1 fusion protein produced at the chromosomal translocation (t (11; 18) (q21; q21)) in Mucosa-associated lymphoid tissue (MALT) lymphoma cleaves the protein at the position of 325th arginine in NIK. By doing so, it has been shown to induce constitutive activation of NIK. This constitutive activation of NIK activates the non-classical NF- ⁇ B pathway, which is involved in cell adhesion and apoptosis resistance (Non-Patent Document 9).
- NIK In diffuse large B-cell lymphoma (DLBCL) cells, NIK is highly expressed in the cytoplasm by BAFF stimulation. The activation of NIK by this high expression is an important signal transduction mechanism involved in the growth of lymphoma, and NIK shRNA suppresses NIK-induced NF- ⁇ B activation in vitro and suppresses the growth of DLBCL cell lines. Is shown (Non-Patent Document 10).
- Non-Patent Document 11 BAFF expression was observed in B lymphoma cells collected from patients with chronic B lymphoma, and it has been shown that this BAFF reduces drug-induced apoptosis. It has also been reported that BAFF overexpressing mice induce the development of B lymphoma (Non-Patent Document 5).
- BAFF expression has also been observed in the serum and lymphoma cells of patients with MALT lymphoma, DLBCL, mantle cell lymphoma, Hodgkin lymphoma and Berkit lymphoma, thereby inducing lymphoma cell proliferation and resistance to apoptosis, BAFF. It has also been shown that patients with high-expression lymphoma have a poorer prognosis than patients with low-expression lymphoma (Non-Patent Document 12, Non-Patent Document 13 and Non-Patent Document 14).
- NIK expression is higher than that of T cells collected from healthy subjects, activating the downstream non-classical NF- ⁇ B pathway, and NF- ⁇ B expression in the nucleus. Higher patients have been shown to have a poorer prognosis than lower patients. It has also been shown that NIK siRNA treatment can induce cell death in peripheral T lymphoma cells (Non-Patent Document 15).
- Non-Patent Documents 16 and 17 It has been reported that BAFF expression in serum is high in patients with acute lymphocytic leukemia, and that there is a correlation between the expression of BAFF and the increase in acute lymphocytic leukemia cells. It has also been shown that tumor cell proliferation is enhanced by non-classical pathway activation mediated by NIK activation by BAFF in acute lymphocytic leukemia cells.
- NIK siRNA treatment non-patent
- Non-Patent Document 22 It has been reported that high NIK expression induces constitutive activation of NF- ⁇ B in Basal-like breast cancer cell lines (Non-Patent Document 22). In addition, BAFF expression is observed in tumor tissues in breast cancer patients, and it has been shown that BAFF enhances the motility of breast cancer cells (Non-Patent Documents 23 and 24).
- Non-Patent Document 25 NIK expression is significantly higher in malignant melanoma than in benign tissue by examination by tissue microarray analysis, and NIK shRNA suppresses tumor growth, induces apoptosis, and arrests cell cycle in vivo. It is recognized (Non-Patent Document 25).
- NF- ⁇ B is activated in non-small cell lung cancer tissues and cell lines, and it has been confirmed that NIK siRNA treatment suppresses apoptosis induction and scaffold-independent cell proliferation (non-small cell lung cancer tissue and cell line).
- Patent Document 26 ).
- Non-Patent Document 27 It has been shown that NIK is highly expressed in liver cancer patients and liver cancer cell lines, and NIK siRNA treatment and miR-520e that reduces NIK expression suppress cell proliferation in vitro and tumor proliferation in vivo. It has been shown to do so (Non-Patent Document 27). In addition, it has been reported that the BAFF concentration in serum is higher in patients with liver cancer than in healthy subjects, and that the progression of the stage and the prognosis of the patient are correlated with the BAFF concentration (Non-Patent Document 28).
- Non-Patent Documents 29 and 30 gastric cancer cells introduced with a mutant that suppresses the activation of NIK suppress the activation of NF- ⁇ B by Helicobacter pylori. It has been shown that the BAFF concentration in feces is increased in patients as compared with healthy subjects (Non-Patent Document 31).
- Non-classical NF- ⁇ B pathway Activation of the non-classical NF- ⁇ B pathway is associated with the development of colitis and colon cancer, and in mice lacking NLRP12, which negatively regulates NIK, non-classical NF- ⁇ B is mediated by NIK activation. It has been shown that the pathway is activated and induces colitis and colon cancer. It has also been reported that the expression of OLFM1 that negatively regulates NIK in colorectal cancer patients is higher in non-cancerous areas than in cancerous areas, and that NIK siRNA treatment in colorectal cancer cells suppresses cell proliferation and motility. (Non-Patent Document 32 and Non-Patent Document 33). Furthermore, it has been shown that in colorectal cancer patients, the higher the serum BAFF concentration, the shorter the progression-free survival and overall survival (Non-Patent Document 34).
- Non-Patent Document 36 Overexpression of NIK and RelB has been observed in patients with renal cancer and has been shown to reduce 10-year survival compared to patients with low expression, and the state of NIK expression is a prognostic factor. has been reported (Non-Patent Document 36). In addition, it has been reported that BAFF expression is higher in renal cancer patients than in healthy subjects, and that the progression of the stage and the prognosis of patients are correlated with BAFF expression (Non-Patent Document 37).
- Non-Patent Documents 38
- NIK mRNA expression is higher in ovarian cancer patient tissues, and the NIK / NF- ⁇ B p52 (non-classical) pathway is activated in ovarian cancer cells, and NIK shRNA treatment depends on the scaffold. It has been shown to suppress sex and non-scaffold-dependent cell proliferation, and further suppress tumor proliferation in vivo with NIK shRNA (Non-Patent Document 39).
- Non-Patent Document 40 In patients with endometrial cancer, it has been shown that the degree of differentiation of cancer tissue decreases and the activation of NIK increases as the stage progresses, and it has been reported that activation of NIK suppresses apoptosis of cancer cells.
- multiple myeloma malignant lymphoma (MALT lymphoma, DLBCL, mantle cell lymphoma, Berkit lymphoma, Hodgkin lymphoma, adult T cell leukemia, peripheral T lymphoma, etc.), pancreatic cancer, breast cancer, malignant melanoma, lung cancer,
- malignant tumors such as liver cancer, gastric cancer, colon cancer, head and neck tumor, lymphoma, renal cancer, ovarian cancer and uterine body cancer
- BAFF overexpression and NIK overexpression occur, and NF- ⁇ B is activated by activation of NIK.
- BAFF NIK activation by BAFF
- NIK activation associated with NIK overexpression BAFF overexpression
- non-classical NF- ⁇ B signaling pathway BAFF overexpression, NIK and non-classical NF.
- CRAB hypercalcemia, renal disorder, anemia, bone lesion
- Osteoclasts such as monoclonal immunoglobulin (M protein) expressed by multiple myeloma cells, immunoglobulin free light chain, interleukin 6 (IL-6) and Macrophage antibody protein 1 ⁇ (MIP-1 ⁇ ) are used for the onset of CRAB. It has been reported that cell activators are involved (Non-Patent Document 41, Non-Patent Document 42 and Non-Patent Document 43).
- M protein and immunoglobulin free light chain caused by multiple myeloma are known to cause renal damage by depositing in the kidney, and also deposit in systemic organs, causing amyloidosis in various organs and causing neuropathy. , Causes various symptoms such as arrhythmia. In addition, it causes hyperviscosity syndrome in blood.
- Non-Patent Document 46 It has been reported that myeloma develops and the expression of M protein is enhanced in NF- ⁇ B2 mutant mice (Non-Patent Document 46). Furthermore, it has been reported that activation of the NF- ⁇ B pathway enhances the expression of osteoclast activators such as IL-6 and MIP-1 ⁇ (Non-Patent Document 47).
- Non-Patent Document 49 IL-6 increases in patient serum as the stage of multiple myeloma progresses and correlates with tumor progression. Furthermore, it has been reported that IL-6 secreted by multiple myeloma promotes the proliferation and survival of multiple myeloma cells by autoclination (Non-Patent Document 49).
- Non-Patent Document 50 MIP-1 ⁇ anti-sense suppresses tumor growth in vivo by inhibiting autoclination
- drugs that can inhibit NIK activation associated with NIK activation and NIK overexpression and suppress the non-classical NF- ⁇ B signaling pathway are M protein and immunoglobulin free light due to multiple myeloma. Renal disorders due to increased chain expression, amyloidosis, bone lesions (bone destruction) due to hyperviscosity syndrome and increased expression of osteolytic cell activator, hypercalcemia associated with bone lesions, pathological fractures, spinal compression fractures, spinal compression It has a therapeutic effect on spinal compression symptoms associated with bone fractures and neurological symptoms associated with spinal compression symptoms. That is, it has a therapeutic effect on CRAB.
- drugs that can inhibit NIK activation and NIK activation associated with NIK overexpression and suppress the non-classical NF- ⁇ B signaling pathway are frequently used by IL-6 and MIP-1 ⁇ autoclins. It has a therapeutic effect on the growth and survival of sex myeloma.
- Patent Document 1 Japanese Patent Laid-Open No. 2016-5318578 discloses a 3- (1H-pyrazole-4-yl) -1H-pyrrolo [2,3-c] pyridine derivative as an NIK inhibitor. ..
- the compound is an inhibitor of NF- ⁇ B-induced kinase, also known as NIK-MAP3K14, and that the compound is a compound for use in the prevention or treatment of cancer. It is recognized as a right.
- Patent Document 1 EC50 for three types of cancer cells (all of which are multiple myeloma cell lines) of JJN-3, L-363, and LP-1 is cited as an example of the compound. .. From the above, it is recognized as common general knowledge that NIK inhibitors have a wide range of therapeutic effects on malignant tumors.
- Patent Document 2 Japanese Unexamined Patent Publication No. 7-082263 discloses that a xanthone compound having the structure of the formula (14) has anticancer activity.
- R 1 to R 7 H, —OH, C1-6 alkyl, C1-6 alkoxy, epoxypropoxy), and a benzophenone compound.
- Patent Document 3 Japanese Unexamined Patent Publication No. 2017-0311466 describes that mangoerin inhibits NIK and is effective for multiple myeloma and malignant melanoma. As described above, compounds having a xanthone skeleton have been found to have anticancer activity.
- Pham LV Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Mediairos LJ, Ford RJ. : Blood. 2011, 117, 200-210. Kern C, Cornuel JF, Billiard C, Tang R, Rulerard D, Stenou V, Defense T, Ajchenbaum-Cymbalista F, Simonin PY, Fel. : Blood. 2004, 103, 679-688. He B, Chadbourn A, Joe E, Schatner EJ, Knowles DM, Cerutti A. : J Immunol. 2004, 172, 3268-3279.
- an object of the present invention is to provide a therapeutic agent and an improving composition agent that inhibit NIK even by oral administration and improve malignant tumors such as malignant lymphoma, lymphocytic leukemia and multiple myeloma. ..
- mangoerin of Patent Document 3 is effective by oral administration, but the required intake is large, and even if it is oral, it cannot be easily ingested. Therefore, a therapeutic agent and an improved composition having higher effect or activity have been sought.
- the present inventors have searched for a compound that inhibits NIK in order to solve the above-mentioned problems.
- a compound having a structure that has not been found so far among substances having a xanthone skeleton has an NIK inhibitory action.
- this substance induces a decrease in the expression of CD138, which is a malignancy marker for multiple myeloma, and an increase in the expression of CD20, which is a B cell marker, and has an effect of inducing conversion from plasma cell-like to B cell-like. It was confirmed that multiple myeloma can be treated in combination with an anti-CD20 monoclonal antibody.
- this substance inhibits monoclonal immunoglobulin production, immunoglobulin free light chain production, and bone destruction-inducing factor production in multiple myeloma, thereby alleviating the symptoms of CRAB associated with multiple myeloma patients. It was confirmed. Furthermore, this substance suppresses cell proliferation and survival of multiple myeloma by inhibiting cell proliferation and survival-related IL-6 and MIP-1 ⁇ secretion in the autocline of multiple myeloma. Confirmation has led to the completion of the present invention.
- novel compound according to the present invention is the compound of the following formulas (1) to (12).
- composition for improving malignant tumor disease is characterized by containing at least one compound among the compounds of the above formulas (1) to (12) as an active ingredient.
- the pharmaceutical composition according to the present invention can improve not only malignant lymphoma, lymphocytic leukemia, and multiple myeloma, but also malignant tumors that have acquired drug resistance such as bortezomib-resistant multiple myeloma and rituximab-resistant malignant lymphoma.
- malignant tumors such as malignant lymphoma, lymphocytic leukemia, multiple myeloma, bortezomib-resistant multiple myeloma and rituximab-resistant malignant lymphoma.
- it does not affect normal cells at a concentration that induces cell death in malignant tumor cells.
- the compound according to the present invention can reduce CD138 known as a marker for myeloma and increase CD20 known as a marker for lymphoma. That is, the plasmacytoma can be returned to a B cell-like state. This is called "B cell-like conversion”.
- Anti-human CD20 monoclonal antibody drugs such as rituximab, obinutuzumab, offatuzumab, and ibritumomab tiuxetan are known as silver bullets for lymphoma of cells having CD20.
- myeloma (plasma cell tumor) can be improved by administering a mixture of the compound of the present invention and an anti-human CD20 monoclonal antibody drug such as rituximab, obinutuzumab, offatuzumab, ibritumomab tiuxetan, which are known as specific agents for lymphoma. can.
- an anti-human CD20 monoclonal antibody drug such as rituximab, obinutuzumab, offatuzumab, ibritumomab tiuxetan, which are known as specific agents for lymphoma. can.
- the above-mentioned malignant tumor promotes the development, proliferation and survival of malignant tumor cells by overexpression of NIK protein. Therefore, it is considered that the improving composition for malignant lymphoma, lymphocytic leukemia, multiple myeloma, etc. according to the present invention has an improving effect not only on the malignant tumor shown in the examples but also on other malignant tumors. ..
- the compound of the present invention can inhibit the production of monoclonal immunoglobulin, immunoglobulin free light chain production and bone destruction-inducing factor associated with multiple myeloma. Therefore, so-called CRAB such as hypercalcemia, renal disorder, anemia, and bone lesion, which are concomitant symptoms associated with these productions, can be improved.
- CRAB such as hypercalcemia, renal disorder, anemia, and bone lesion
- the compound of the present invention contains M protein, immunoglobulin free light chain, renal disorders due to increased expression of IL-6, MIP-1 ⁇ , etc., amyloidosis, hyperviscosity syndrome, and bone lesions due to increased expression of bone fracture cell activator. (Bone destruction), hypercalcemia associated with bone lesions, pathological fractures, spinal compression fractures, spinal compression symptoms associated with spinal compression fractures, and neurological symptoms associated with spinal compression symptoms can be suppressed. That is, the expression of CRAB can be suppressed.
- the compounds of the invention can suppress IL-6 and MIP-1 ⁇ production in multiple myeloma. Therefore, it is possible to suppress the proliferation and survival of autocline cells caused by IL-6 and MIP-1 ⁇ in multiple myeloma.
- novel compound according to the present invention and a pharmaceutical composition containing the novel compound as an active ingredient for improving malignant tumor diseases such as malignant lymphoma, lymphocytic leukemia, multiple myeloma, voltezomib-resistant multiple myeloma and rituximab-resistant malignant lymphoma. Etc. will be explained. It should be noted that the following description is an example of one embodiment and one embodiment of the present invention, and the present invention is not limited to the following description. The following embodiments may be modified without departing from the spirit of the present invention.
- improvement may include not only treatment of a target disease or symptom but also reduction and suppression of symptom.
- inhibittion of cell proliferation may include not only slowing the proliferation rate of the target cell, but also meaning that the cell does not proliferate, the cell dies, or the function of the cell is lost.
- novel compound according to the present invention is represented by the formulas (1) to (12) having a xanthone skeleton.
- the "compound according to the present invention” may refer to at least one of the following 12 compounds.
- Equation (1) is 2', 3', 4', 6'-tetra-O-valeryl mangiferin (hereinafter referred to as "yk-7").
- Equation (2) is 1,3,2', 3', 4', 6,6', 7-octa-O-valeryl mangiferin (hereinafter referred to as "yk-8-1").
- Equation (3) is 1,2', 3', 4', 6-penta-O-valeryl mangiferin (hereinafter referred to as "yk-8-3").
- Equation (4) is 1,3,2', 3', 4', 6,6', 7-octa-O-propionylmangiferin (hereinafter referred to as "M7").
- Equation (5) is 2', 3', 4', 6'-tetra-O-propionylmangiferin (hereinafter referred to as "M9").
- Equation (6) is 1,3,2', 3', 4', 6,6', 7-octa-O-butyryl mangiferin (hereinafter referred to as "M11").
- Equation (7) is 1,2', 3', 4', 6-penta-O-butyryl mangiferin (hereinafter referred to as "M12").
- Equation (8) is 2', 3', 4', 6'-tetra-O-butyryl mangiferin (hereinafter referred to as "M14").
- Equation (9) is 2', 3', 4', 6'-tetra-O-pivaloylmangiferin (hereinafter referred to as "M15").
- Equation (10) is 2', 3'-di-O-butyl-4', 6'-di-O-butyryl mangiferin (hereinafter referred to as "M16").
- Equation (11) is 3,6,7-trihydroxy-1- (2-hydroxyethoxy) -9H-xanthene-9-one (hereinafter referred to as "M18").
- Equation (12) is 1-allyloxy-3,6,7-trihydroxy-9H-xanthene-9-one (hereinafter referred to as "M19").
- compositions for inhibiting the growth of malignant tumor cells such as malignant lymphoma, lymphocytic leukemia, multiple myeloma, bortezomib-resistant multiple myeloma and rituximab-resistant malignant lymphoma. Its mechanism of action is to inhibit NIK in the intracellular transduction pathway. Therefore, the composition for inhibiting the growth of malignant tumor cells according to the present invention is not limited to the above, but pancreatic cancer, breast cancer, malignant melanoma, lung cancer, liver cancer, gastric cancer, colon cancer, head and neck tumor, glioma, renal cancer, etc. It can also inhibit the growth of cancer cells such as ovarian cancer and uterine body cancer.
- composition for inhibiting the growth of malignant tumor cells according to the present invention contains at least one of the compounds according to the present invention as an active ingredient.
- the compound according to the present invention is a relatively low molecular weight compound like mangoerin, is well soluble in water, can be ingested orally, and does not exert an effect of inhibiting cell proliferation on normal cells. Therefore, when applied to the human body, it is expected to work as an improved composition with few side effects. Therefore, the compound according to the present invention can be used as a pharmaceutical composition for improving malignant tumor diseases.
- the pharmaceutical composition for improving a malignant tumor disease according to the present invention contains at least one of the above 12 compounds according to the present invention as an active ingredient. It may also contain other components that are acceptable as a drug.
- the pharmaceutical composition according to the present invention can exert its effect by oral administration. Therefore, it can be provided as an internal preparation.
- a powdery composition for improving malignant tumor disease can be provided as a formulation into capsules, granules, powders, tablets and the like.
- additives such as binders, lubricants, disintegrants, colorants, flavoring agents, preservatives, antioxidants and stabilizers, and add capsules, granules, powders and tablets. It can be manufactured by a conventional method.
- the pharmaceutical composition according to the present invention can be administered by intravenous, subcutaneous or intramuscular injection.
- the pharmaceutical composition according to the present invention may be formulated into an external preparation such as a liquid, an ointment, a cream, a gelling agent, a patch, or an aerosol, and administered parenterally.
- an external preparation such as a liquid, an ointment, a cream, a gelling agent, a patch, or an aerosol, and administered parenterally.
- water, a lower alcohol, a solubilizing agent, a surfactant, an emulsion stabilizer, a gelling agent, a pressure-sensitive adhesive, and other necessary base components can be blended.
- additives such as vasodilators, corticosteroids, keratolytic agents, moisturizers, fungicides, antioxidants, refreshing agents, fragrances, and pigments may be appropriately added.
- the pharmaceutical composition according to the present invention can be used not only for multiple myeloma but also for lymphocytic leukemia and malignant lymphoma (MALT lymphoma, DLBCL, Berkit lymphoma). , Hodgkin's lymphoma, adult T-cell leukemia, peripheral T-lymphoma, etc.) It can improve malignant tumor diseases such as renal cancer, ovarian cancer and uterine body cancer.
- lymphocytic leukemia and malignant lymphoma MALT lymphoma, DLBCL, Berkit lymphoma
- Hodgkin's lymphoma adult T-cell leukemia, peripheral T-lymphoma, etc.
- malignant tumor diseases such as renal cancer, ovarian cancer and uterine body cancer.
- the compound according to the present invention produces monoclonal immunoglobulins such as IgG, immunoglobulin free light chains, and osteoclast activators such as IL-6 and MIP-1 ⁇ from cancerous plasma cells. Since it suppresses, the pharmaceutical composition according to the present invention is also a pharmaceutical composition for improving symptoms such as CRAB (hypercalcemia, renal disorder, anemia, bone lesion) known as a concomitant symptom of multiple myeloma. become.
- CRAB hypercalcemia, renal disorder, anemia, bone lesion
- the compound according to the present invention also suppresses the production of monoclonal immunoglobulins such as IgG and immunoglobulin free light chains by suppressing cancerous plasma cells.
- Amyloidosis and hyperviscosity syndrome caused by these overproductions are not included in CRAB. However, it can be said to be a concomitant symptom of multiple myeloma. Therefore, in the present specification, amyloidosis and hyperviscosity syndrome are added to CRAB and are referred to as "CRAB and the like".
- the pharmaceutical composition according to the present invention is also a pharmaceutical composition for improvement such as CRAB.
- the compound according to the present invention can reduce CD138 known as a marker of multiple myeloma and increase CD20 known as a marker of lymphoma. That is, the plasmacytoma can be returned to a B cell-like state. This is called "B cell-like conversion”.
- Anti-human CD20 monoclonal antibody drugs such as rituximab, obinutuzumab, offatuzumab, and ibritumomab tiuxetan are known as specific drugs for cancer of cells having CD20 (malignant lymphoma).
- multiple myeloma (plasma cell tumor) is improved by administering a mixture of the compound of the present invention and an anti-human CD20 monoclonal antibody drug such as rituximab, obinutuzumab, offatuzumab, and ibritumomab tiuxetan, which are known as silver bullets for lymphoma. It can be a pharmaceutical composition.
- the compound of the present invention as an active ingredient, it is possible to provide a conversion inducer that converts multiple myeloma cells into B cell-like substances.
- the compound according to the present invention suppresses the production of IL-6 and MIP-1 ⁇ involved in promoting the growth of multiple myeloma by autoclination, it can be a pharmaceutical composition that suppresses the growth of multiple myeloma. Further, since the compound according to the present invention suppresses IL-6 and MIP-1 ⁇ , it can also be used as an IL-6 inhibitor or a MIP-1 ⁇ inhibitor.
- the compound according to the present invention can also be provided as a processed food or an agent. That is, even if the compound according to the present invention is ingested as a processed food or an agent, it has the same effect as the improving pharmaceutical composition according to the present invention.
- the agent includes supplements and additives.
- Processed foods or agents include, for example, candy, gum, jelly, biscuits, cookies, rice cakes, bread, noodles, fish / meat paste products, tea, soft drinks, coffee drinks, dairy drinks, dairy drinks, lactic acid bacteria drinks, yogurt. Not only general processed foods including favorite foods such as ice cream and pudding and health foods, but also health functional foods such as specified health foods and nutritional functional foods stipulated in the health functional food system of the Ministry of Health, Labor and Welfare. Dietary supplements, feeds, food additives, etc. are also included in processed foods or agents.
- the processed food according to the present invention can be prepared by adding a composition for improving a malignant tumor disease to the raw materials of these processed foods or agents. It may be said that the addition of the compound according to the present invention to a processed food or agent is added as an active ingredient.
- the processed food or agent according to the present invention includes multiple myeloma, lymphocytic leukemia, malignant lymphoma (MALT lymphoma, DLBCL, mantle cell lymphoma, Berkit lymphoma, Hodgkin lymphoma, adult T cell leukemia, peripheral T lymphoma, etc.).
- MALT lymphoma malignant lymphoma
- DLBCL mantle cell lymphoma
- Berkit lymphoma Hodgkin lymphoma
- adult T cell leukemia peripheral T lymphoma, etc.
- Voltezomib-resistant multiple myeloma, rituximab-resistant malignant lymphoma, pancreatic cancer, breast cancer, malignant melanoma, lung cancer, liver cancer, gastric cancer, colon cancer, head and neck tumor, glioma, renal cancer, ovarian cancer and uterine body cancer It may be said that it is a processed food or agent with a label indicating that it is for improvement.
- the processed food or agent according to the present invention includes CRAB (renal disorder, amyloidosis, hyperviscosity syndrome, bone lesion (bone destruction), hypercalcemia associated with bone lesion, pathological fracture) associated with multiple myeloma.
- CRAB renal disorder, amyloidosis, hyperviscosity syndrome, bone lesion (bone destruction), hypercalcemia associated with bone lesion, pathological fracture
- Spinal compression fracture Spinal compression symptom associated with spinal compression fracture
- Neurological symptom associated with spinal compression symptom Neurological symptom associated with spinal compression symptom
- the compounds according to the present invention include multiple myeloma, lymphocytic leukemia, malignant lymphoma (MALT lymphoma, DLBCL, mantle cell lymphoma, Berkit lymphoma, Hodgkin lymphoma, adult T cell leukemia, peripheral T lymphoma, etc.), voltezomib.
- malignant tumors such as resistant multiple myeloma, rituximab-resistant malignant lymphoma, pancreatic cancer, breast cancer, malignant melanoma, lung cancer, liver cancer, gastric cancer, colon cancer, head and neck tumor, glioma, renal cancer, ovarian cancer and uterine body cancer Therefore, it may be used as a composition for inhibiting cell proliferation.
- the washed ethyl acetate layer was dried over anhydrous sodium sulfate, filtered and concentrated to obtain a pale yellow liquid (1.09 g).
- the obtained pale yellow liquid, N, N-dimethyltrimethylenediamine (0.63 mL, 5.05 mmol) and dimethyl sulfoxide (10 mL) were stirred at 50 ° C. for 3 hours.
- the reaction mixture was poured into ice water (50 mL) and extracted with a mixed solution of diethyl ether and hexane (3/1).
- the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated.
- the residue was purified by column chromatography (CHCl 3 / MeOH) to give the title compound (589 mg, 0.87 mmol, 86%) as a pale yellow solid.
- mangoerin 8a (M8) was synthesized.
- Mangoerin 8a was synthesized as follows. 1,3,2', 3', 4', 6,6', 7-octa-O-propionylmangiferin (M7) (5.06 g, 5.68 mmol), ammonium acetate (6.7 g, 87.0 mmol) ), Methanol (160 mL) and water (20 mL) were stirred at room temperature for 6 hours. Methanol was distilled off from the reaction solution by concentration under reduced pressure, and the residue was diluted with ethyl acetate (100 mL).
- Mangoerin 8a is represented by the formula (a).
- Nolaciliol was synthesized according to the method of Non-Patent Document 48.
- Nolaciliol is a known substance represented by CAS No. 3542-72-1 and is also commercially available, so it may be purchased.
- Noraciliol was synthesized as follows. That is, according to the method described in the document (Non-Patent Document 48), 2,4,5-trimethoxybenzoic acid (Compound II) is treated with thionyl chloride to obtain 2,4,5-trimethoxybenzoic acid chloride (Compound III). rice field. Next, 2-hirodoxy-2', 4,4', 5,6'-by the Friedel-Craft reaction between the obtained compound (Compound III) and 1,3,5-trimethoxybenzene (Compound IV). Pentamethoxybenzophenone (Compound V) was obtained.
- this compound (V) is treated with tetrabutylammonium hydroxide to obtain 1,3,6,7-tetramethoxyxanthone (compound VI), and then demethylation is performed to obtain nolacyol (compound I). It was obtained in a yield of 39%.
- the extract was washed with saturated brine, dried over anhydrous sodium sulfate, the desiccant was filtered off with fold filter paper, and the filtrate was distilled off under reduced pressure to obtain a crude product.
- Example 1 Examination of cell death-inducing effect of each compound on KMS-28BM cells> KMS-28BM cells (myeloma cell line) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding KMS-28BM cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- Table 1 shows the results of calculating the IC50 (half-inhibition concentration: the same applies hereinafter) value.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that the cell death of the myeloma cell line KMS-28BM cells was induced at a concentration lower than or equivalent to that of the group (a) administered.
- L363 cells (myeloma cell line) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding L363 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the description of "1,3,5,7,9,11” is omitted in the graph, but the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2". It is assumed that the reference numeral "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that the cell death of the myeloma cell line L363 cells was induced at a concentration lower than or equivalent to that of the administration group ((a)).
- RPMI8226 cells (myeloma cell line) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding RPMI8226 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- Table 3 shows the results of calculating the IC50 value.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that the cell death of the myeloma cell line RPMI8226 cells was induced at a concentration lower than or equivalent to that of the administration group ((a)).
- RPMI8226 / B cells (bortezomib-resistant myeloma cell line) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding RPMI8226 / B cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- Table 4 shows the results of calculating the IC50 value.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found to induce cell death of the Voltezomib-resistant myeloma cell line RPMI8226 / B cells at a concentration lower than or equivalent to that of the (a) -administered group.
- Rec-1 (mantle cell lymphoma cell line) was cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding Rec-1 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that the mantle cell lymphoma cell line Rec-1 cells were induced to die at a concentration lower than or equivalent to that of the (a) -administered group.
- ⁇ Example 6 Examination of cell death-inducing effect of each compound on Raji cells> Raji cells (Burkitt lymphoma) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding Raji cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that the cell death of Razi cells, which are Berkit lymphomas, was induced at a concentration lower than or equivalent to that of the group (a) administered.
- FIG. 7 shows the state of rituximab resistance of RR1 cells.
- the horizontal axis represents the rituximab concentration ( ⁇ g / mL) and the vertical axis represents the cell viability (%).
- the concentration of rituximab increased in both Raji cells and RR1 cells, the cell viability decreased.
- RR1 cells had a higher cell viability and had resistance to rituximab.
- the IC50 of Razi cells to rituximab was 0.121 ⁇ g / mL, whereas the IC50 of RR1 cells to rituximab was 98 ⁇ g / mL, which was about 809 times more resistant to Raji cells. ..
- RR1 cells (Rituximab-resistant cell line of Burkitt lymphoma) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding RR1 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- Table 7 shows the results of calculating the IC50 value.
- these substances having a xanthone skeleton were able to induce cell death in RR1 cells, which are rituximab-resistant Burkitt lymphoma cells.
- SU-DHL-4 cells (diffuse large B-cell lymphoma) were cultured under the conditions of 5% CO 2 , 37 ° C.
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding SU-DHL-4 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that SU-DHL-4 cells, which are diffuse large B-cell lymphomas, were induced to die at a concentration lower than or equivalent to that in the group (a).
- CCRF-SB acute lymphocytic leukemia
- CCRF-SB cells acute lymphocytic leukemia cell line
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum.
- compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- Table 9 shows the results of calculating the IC50 value.
- the IC50 value of the yk-8-1 (formula (2)) administration group was high, the yk-7 (formula (1)) administration group, the yk-8-3 ((3) equation) administration group, and M7 (((1) equation) administration group. 4) formula) administration group, M9 ((5) formula) administration group, M11 ((6) formula) administration group, M12 ((7) formula) administration group, M14 ((8) formula) administration group, M15 (((8) formula) 9) formula) administration group, M16 ((10) formula) administration group, M18 ((11) formula) administration group, M19 ((12) formula) administration group includes nolacyol ((n) formula) administration group and mangiferin 8a. It was found that the cell death of CCRF-SB cells, which are acute lymphocytic leukemia, was induced at a concentration lower than or equivalent to that of the group (a) administered.
- MEC-1 cells chronic lymphocytic leukemia cell line
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding MEC-1 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- the symbols and arrows of "5, 6, 7, 8, 9, 10, 11, 12" are shown from the left.
- the code "5" is the M9 (formula (5)) administration group
- the code "6” is the M11 (formula (6)) administration group
- the code "7” is the M12 (formula (7)) administration group.
- Table 10 shows the results of calculating the IC50 value.
- the M16 (type (10)) administration group, the M18 ((11) type) administration group, and the M19 ((12) type) administration group showed cell death of MEC-1 cells, which are chronic lymphocytic leukemia cell lines, at low concentrations. It was found to induce.
- HUT-78 peripheral T lymphoma
- HUT-78 cells peripheral T lymphoma cell line
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum.
- compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- the symbols and arrows of "5, 6, 7, 8, 9, 10, 11, 12" are shown from the left.
- the code "5" is the M9 (formula (5)) administration group
- the code "6” is the M11 (formula (6)) administration group
- the code "7” is the M12 (formula (7)) administration group.
- Table 11 shows the results of calculating the IC50 value.
- the M16 (type (10)) administration group, the M18 ((11) type) administration group, and the M19 ((12)) administration group induce cell death of HUT-78 cells, which are peripheral T lymphoma cell lines, at low concentrations. Was allowed to do.
- ATN-1 cells adult T-cell leukemia strain
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding ATN-1 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- the symbols and arrows of "5, 6, 7, 8, 9, 10, 11, 12" are shown from the left.
- the code "5" is the M9 (formula (5)) administration group
- the code "6” is the M11 (formula (6)) administration group
- the code "7” is the M12 (formula (7)) administration group.
- Table 12 shows the results of calculating the IC50 value.
- the M16 (type (10)) administration group, the M18 ((11) type) administration group, and the M19 ((12) type) administration group showed cell death of ATN-1 cells, which are adult T-cell leukemia cell lines, at low concentrations. It was found to induce.
- RPMI1788 cells human normal B cell line
- the culture medium used was RPMI-1640 medium supplemented with 100 ⁇ g / mL penicillin, 100 U / mL streptomycin and fetal bovine serum. After seeding RPMI1788 cells in 96-well plate, compounds of each concentration were added, and the cell viability was measured by the trypan blue die method. The results are shown in FIG.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- each bar is indicated by an arrow with the sign "n, a, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12" from the left. Is done.
- the reference numeral "1” is indicated by an arrow between the reference numerals "a” and "2”. It is assumed that "3" is written between the reference numerals "2" and the reference numeral "4", and other odd numbers are similarly described by the arrows between the preceding and following even codes.
- the code [n] is a nolacyol (type (n)) administration group
- the code “a” is a mangiferin 8a (type (a)) administration group
- the code “1” is a yk-7 (type (1)) administration group.
- “2" is the yk-8-1 (formula (2)) administration group
- the code “3” is the yk-8-3 (formula (3)) administration group
- the code "4" is the M7 (formula) administration.
- Table 13 shows the results of calculating the IC50 value.
- the IC50 values of the yk-7 (formula (1)) administration group and the yk-8-3 ((3) equation) administration group were low, but the nolacyol ((n) equation) administration group shown as a comparative example.
- the nolacyol ((n) equation) administration group shown as a comparative example.
- the compound according to the present invention can be a therapeutic agent with few side effects for lymphoma and myeloma.
- Example 14 Effect of administration of each compound on the signal system Examination of inhibition of NIK activation> As a result of examining the NIK inhibitory effect by administration of each compound using KMS-28BM cells and the activation kinetics of IKK, NF- ⁇ B p52, and NF- ⁇ B p65, which are downstream signals of NIK, by immunobloating, NIK activation Inhibition, inhibition of IKK activity, and inhibition of nuclear translocation of NF- ⁇ B p52 and NF- ⁇ B p65 were observed (FIGS. 15 and 16).
- KMS-28BM cells were seeded in 150 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 72 hours (Control), and KMS-28BM cells were seeded in 150 cm 2 flasks, and after culturing 24 hours before, 1 ⁇ M mangiferin 8a, 1 ⁇ M noratoriol, 0.5 ⁇ M M7 (formula (4)), 1 ⁇ M M8 (mangiferin 8a: duplicated publication), 0.2 ⁇ M M9 (formula (5)), 5 ⁇ M yk-7 (formula (1)), Add the cells to the final concentrations of 0.5 ⁇ M yk-8-3 (formula (3)) and 100 ⁇ M yk-8-1 (formula (2)) for 72 hours under the conditions of 37 ° C.
- the cytoplasmic fraction and the cytosol fraction were extracted using ProteoExtract (registered trademark) Subcellular Proteome Execution Kit manufactured by Merck Co., Ltd.
- each sample is transferred to the PVDF membrane and transferred to anti-phospho-NIK antibody, anti-NIK antibody, anti-phospho-IKK antibody, anti-IKK antibody, anti- ⁇ -actin antibody, anti-NF- ⁇ Bp52 antibody and anti-NF- ⁇ Bp65.
- the assay was performed using an antibody and an anti-Lamin antibody.
- FIGS. 15 and 16 The results of immunobloating are shown in FIGS. 15 and 16.
- Control 1 ⁇ M mangoerin 8a, 1 ⁇ M nolacyol, 0.5 ⁇ M M7 (formula (4)), 1 ⁇ M M8 (mangoerin 8a: duplicated publication), 0.2 ⁇ M M9 (formula (5)) in the horizontal direction of the photograph.
- the cases where 5, 5 ⁇ M yk-7 (formula (1)), 0.5 ⁇ M yk-8-3 (formula (3)) and 100 ⁇ M yk-8-1 (formula (2)) were added are shown side by side.
- FIG. 15 Control, 1 ⁇ M mangoerin 8a, 1 ⁇ M nolacyol, 0.5 ⁇ M M7 (formula (4)), 1 ⁇ M M8 (mangoerin 8a: duplicated publication), 0.2 ⁇ M M9 (formula (5)) in the horizontal direction of the photograph.
- the antibody species was shown in the vertical direction. Specifically, in the case of an anti-phospho-NIK antibody (described as "Phospho-NIK”), in the case of an anti-NIK antibody (described as "NIK”), an anti-phospho-IKK antibody (described as “Phospho-IKK”), Anti-IKK antibody (described as “IKK”), anti- ⁇ -actin antibody (described as " ⁇ -actin”), anti-NF- ⁇ Bp52 antibody (described as "NF- ⁇ Bp52nuclear”), anti-NF- ⁇ Bp65 antibody (described as "NF- ⁇ Bp52nuclear”). NF- ⁇ Bp65 nuclear) and anti-Lamin antibody (described as “Lamin”).
- NF- ⁇ Bp52 nuclear anti-NF- ⁇ Bp52 antibody
- anti-NF- ⁇ Bp65 antibody described as “NF- ⁇ Bp65 nuclear”
- anti-Lamin antibody described as “Lamin”
- Lamin is present regardless of all compounds, but NF- ⁇ Bp52 in the nucleus is mangoerin 8a, nolacyol, M7 (formula (4)), M8 (mangoferin 8a: duplicate publication), M9 (formula (5)).
- Lamin is a fibrous protein that maintains structure and regulates transcription in the cell nucleus. Therefore, it is shown that NF- ⁇ Bp65 and NF- ⁇ Bp52 in the nucleus do not exist or are very small even if each compound is added in the state where the nuclear substance is detected in all the samples. ing.
- Example 15 CD138 expression inhibitory effect by administration of each compound to KMS-28BM cells> As a result of examining the CD138 expression inhibitory effect by administration of each compound using KMS-28BM cells by Flow cytometry, the CD138 expression inhibitory effect was confirmed.
- KMS-28BM cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control), and KMS-28BM cells were seeded in 75 cm 2 flasks, and after 4 hours of pre-culture, 0.05 ⁇ M M7, 0.05 ⁇ M M9, 0.1 ⁇ M yk-7, 0.1 ⁇ M yk-8-3, 50 ⁇ M yk-8-1, 0.5 ⁇ M M11, 0.05 ⁇ M M12, 0.005 ⁇ M M14, 0.
- the cells were added at final concentrations of 005 ⁇ M M15, 0.005 ⁇ M M16, 0.5 ⁇ M M18 and 0.5 ⁇ M M19, and cultured at 37 ° C. under 5% CO 2 conditions for 10 days. This addition amount is a concentration lower than that of IC50 of the above compound with respect to KMS-28BM. After culturing for 10 days, cells were stained with anti-CD138 antibody, which is a malignancy marker for multiple myeloma, and expression of CD138 was measured using BD LSRFortessa.
- the results are shown in FIGS. 17, 18, 19 and 20.
- the horizontal axis represents the expression level of CD138, and the vertical axis represents the number of cells.
- the solid line in the panel is the Negative control without treatment of the compound and the isotype control antibody, the dotted line is the Positive control without the compound and the treatment with the anti-CD138 antibody, and the broken line is the treatment with the compound and the anti-CD138 antibody. Is shown. Compared with the Negative control group treated with the isotype control antibody without treating the compound, the expression of CD138 was significantly increased in the Positive control.
- M7 administration group (FIG. 17 (a)), M9 administration group (FIG. 17 (b)), yk-7 administration group (FIG. 17 (c)), yk-8-3 administration group (FIG. 18 (a)), yk-8-1 administration group (FIG. 18 (b)), M11 administration group (FIG. 19 (a)), M12 administration group (FIG. 19 (b)), M14 administration group (FIG. 19 (c)), M15 administration.
- FIG. 19 (d) M16-administered group
- FIG. 20 (b) M18-administered group
- M19-administered group (FIG.
- the positive control was significantly compared with the positive control.
- the expression level of CD138 decreased and was almost the same as that of the Negative control. That is, M7, M9, yk-7, yk-8-3, yk-8-1, M11, M12, M14, M15, M16, M18, and M19 suppress the expression of CD138, which is a malignancy marker for multiple myeloma. I found out that I would do it.
- Example 16 Effect of increasing CD20 expression by administration of each compound in KMS-28BM cells> As a result of examining the effect of increasing the expression of CD20 by administration of each compound using KMS-28BM cells by Flow cytometry, the effect of increasing the expression of CD20 was confirmed.
- KMS-28BM cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control), and KMS-28BM cells were seeded in 75 cm 2 flasks, and after 4 hours of pre-culture, 0.05 ⁇ M M7, 0.05 ⁇ M M9, 0.1 ⁇ M yk-7, 0.1 ⁇ M yk-8-3, 50 ⁇ M yk-8-1, 0.5 ⁇ M M11, 0.05 ⁇ M M12, 0.005 ⁇ M M14, 0.
- the cells were added at final concentrations of 005 ⁇ M M15, 0.005 ⁇ M M16, 0.5 ⁇ M M18 and 0.5 ⁇ M M19, and cultured at 37 ° C. under 5% CO 2 conditions for 10 days. This addition amount is a concentration lower than that of IC50 of the above compound with respect to KMS-28BM. After culturing for 10 days, cells were stained with anti-CD20 antibody, which is a B cell marker, and expression of CD20 was measured using BD LSRFortessa. CCRF-SB cells were used as a CD20 positive control.
- the results are shown in FIGS. 21, 22, 23, and 24.
- the horizontal axis represents the expression level of CD20, and the vertical axis represents the number of cells.
- the solid line in the panel is the Negative control without treating the compound and the isotype control antibody is treated
- the dotted line is the Positive control without treating the compound and treated with the anti-CD20 antibody
- the broken line is the one treated with the compound and the anti-CD20 antibody. Is shown.
- the alternate long and short dash line shows CCRF-SB cells (leukemia, acute B lymphocytic leukemia cells) treated with anti-CD20 antibody.
- CCRF-SB cells used as the CD20 positive control the expression of CD20 was significantly increased as compared with the Negative control and Positive control of KMS-28BM cells. This indicates that CCRF-SB cells express CD20.
- the M7 administration group (FIG. 21 (a)), the M9 administration group (FIG. 21 (b)), the yk-7 administration group (FIG. 21 (c)), and the yk-8-3 administration group (FIG. 22 (a)).
- Yk-8-1 administration group (FIG. 22 (b)), M11 administration group (FIG. 23 (a)), M12 administration group (FIG. 23 (b)), M14 administration group (FIG. 23 (c)), The M15-administered group (FIG. 23 (d)), the M16-administered group (FIG. 24 (a)), the M18-administered group (FIG.
- Example 17 CD138 expression inhibitory effect by administration of each compound in L363 cells> As a result of examining the CD138 expression inhibitory effect by administration of each compound using L363 cells by Flow cytometry, the CD138 expression inhibitory effect was confirmed.
- L363 cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control). L363 cells were seeded in 75 cm 2 flasks, and after 4 hours of preculture, 0.1 ⁇ M M7. , 0.05 ⁇ M M9, 0.1 ⁇ M yk-7, 0.1 ⁇ M yk-8-3, 50 ⁇ M yk-8-1, 0.1 ⁇ M M11, 0.01 ⁇ M M12, 0.005 ⁇ M M14, 0.005 ⁇ M M15, 0 The cells were added at a final concentration of .005 ⁇ M M16, 1 ⁇ M M18 and 1 ⁇ M M19, and cultured at 37 ° C.
- the results are shown in FIGS. 25, 26, 27, and 28.
- the horizontal axis represents the expression level of CD138, and the vertical axis represents the number of cells.
- the solid line in the panel is the Negative control without treatment of the compound and the isotype control antibody, the dotted line is the Positive control without the compound and the treatment with the anti-CD138 antibody, and the broken line is the treatment with the compound and the anti-CD138 antibody. Is shown.
- M7 administration group (FIG. 25 (a)), M9 administration group (FIG. 25 (b)), yk-7 administration group (FIG. 25 (c)), yk-8-3 administration group (FIG. 26 (a)), yk-8-1 administration group (FIG. 26 (b)), M11 administration group (FIG. 27 (a)), M12 administration group (FIG. 27 (b)), M14 administration group (FIG. 27 (c)), M15 administration.
- the group (FIG. 27 (d)), M16-administered group (FIG. 28 (a)), M18-administered group (FIG.
- Example 18 Effect of increasing CD20 expression by administration of each compound in L363 cells> As a result of examining the effect of increasing the expression of CD20 by administration of each compound using L363 cells by Flow cytometry, the effect of increasing the expression of CD20 was confirmed.
- L363 cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control). L363 cells were seeded in 75 cm 2 flasks, and after 4 hours of preculture, 0.1 ⁇ M M7. , 0.05 ⁇ M M9, 0.1 ⁇ M yk-7, 0.1 ⁇ M yk-8-3, 50 ⁇ M yk-8-1, 0.1 ⁇ M M11, 0.01 ⁇ M M12, 0.005 ⁇ M M14, 0.005 ⁇ M M15, 0 The cells were added at a final concentration of .005 ⁇ M M16, 1 ⁇ M M18 and 1 ⁇ M M19, and cultured at 37 ° C.
- the results are shown in FIGS. 29, 30, 31, and 32.
- the horizontal axis represents the expression level of CD20, and the vertical axis represents the number of cells.
- the solid line in the panel is the Negative control without treating the compound and the isotype control antibody is treated
- the dotted line is the Positive control without treating the compound and treated with the anti-CD20 antibody
- the broken line is the one treated with the compound and the anti-CD20 antibody. Is shown.
- the alternate long and short dash line shows CCRF-SB cells treated with anti-CD20 antibody.
- the CD20 expression was hardly increased in the Positive control, which was similar to that of the Negative control. That is, it can be seen that the L363 cells do not express CD20.
- CD20 expression was significantly increased as compared with the Negative control and Positive control of L363 cells.
- CCRF-SB cells express CD20.
- Yk-8-1 administration group (FIG. 30 (b)) M11 administration group (FIG. 31 (a)), M12 administration group (FIG. 31 (b)), M14 administration group (FIG. 31 (c)), The M15-administered group (FIG. 31 (d)), the M16-administered group (FIG. 32 (a)), the M18-administered group (FIG.
- Example 19 Cell death-inducing effect of rituximab combined use via CD20 expression induction by administration of each compound in KMS-28BM cells> After inducing an increase in CD20 expression by administration of each compound using KMS-28BM cells, the cell death-inducing effect of rituximab, which is an anti-CD20 monoclonal antibody, was examined. As a result, a cell-killing effect was observed by the combined use of each compound and rituximab.
- KMS-28BM cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control), and KMS-28BM cells were seeded in 75 cm 2 flasks, and after culturing 24 hours before, Add to a final concentration of 0.1 ⁇ M M9, 0.01 ⁇ M M14, 0.01 ⁇ M M15, 0.01 ⁇ M M16, 0.5 ⁇ M M18 and 0.5 ⁇ M M19 under the conditions of 37 ° C. and 5% CO 2 . The cells were cultured for 10 days. This addition amount is a concentration lower than that of IC50 of the above compound with respect to KMS-28BM.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- "*" was shown for those with a significant difference (P ⁇ 0.01) with respect to the control of the target group.
- Example 20 Cell death-inducing effect of rituximab combined use via CD20 expression induction by administration of each compound in L363 cells> After inducing an increase in CD20 expression by administration of each compound using L363 cells, the cell death-inducing effect of rituximab, which is an anti-CD20 monoclonal antibody, was examined. As a result, a cell-killing effect was observed by the combined use of each compound and rituximab.
- L363 cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control). L363 cells were seeded in 75 cm 2 flasks, and after culturing 24 hours before, 0.1 ⁇ M M9. , 0.01 ⁇ M M14, 0.01 ⁇ M M15, 0.01 ⁇ M M16, 0.5 ⁇ M M18 and 0.5 ⁇ M M19 were added to the final concentration and cultured at 37 ° C. and 5% CO 2 for 10 days. .. This addition amount is a concentration lower than that of IC50 of the above compound with respect to L363.
- the horizontal axis shows the concentration of each compound, and the vertical axis shows the cell viability (%).
- the control was prepared by adding only 0.5% DMSO in PBS used for dissolving the reagent.
- "*" was shown for those with a significant difference (P ⁇ 0.01) with respect to the control of the target group.
- CD138 decreased, CD20 increased, and the morphology of both myeloma cells KMS-28BM and L363 returned to B cell-like (in this case, lymphoma).
- cell death induction was obtained by the combined use of rituximab through an increase in CD20.
- anti-human CD20 monoclonal antibody drugs such as rituximab, obinutuzumab, offatsuzumab, and ibritumomab tiuxetan are known as silver bullets for lymphoma expressing CD20.
- an anti-human CD20 monoclonal antibody drug such as rituximab, obinutuzumab, offatuzumab, ibritumomab tiuxetan and the like and a compound according to the present invention can be mixed and administered to obtain a therapeutic agent for multiple myeloma.
- Example 21 IgG secretion inhibitory effect by administration of each compound in KMS-28BM cells> As a result of examining the IgG secretion inhibitory effect by administration of each compound using KMS-28BM cells by an enzyme-linked immunosorbent assay (ELISA), an IgG secretion inhibitory effect was observed.
- ELISA enzyme-linked immunosorbent assay
- KMS-28BM cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control), and KMS-28BM cells were seeded in 75 cm 2 flasks, and after 4 hours of pre-culture, M7 is 0.05 ⁇ M, M9 is 0.01 ⁇ M, yk-7 is 0.5 ⁇ M, yk-8-3 is 0.05 ⁇ M, yk-8-1 is 50 ⁇ M, M11 is 0.5 ⁇ M, and M12 is 0.05 ⁇ M.
- M14 was added at a final concentration of 0.005 ⁇ M, M15 at 0.005 ⁇ M, M16 at 0.005 ⁇ M, M18 at 0.5 ⁇ M, and M19 at a final concentration of 0.5 ⁇ M under the conditions of 37 ° C. and 5% CO 2 . Incubated for 10 days. After culturing for 10 days, the culture supernatant was collected and the amount of IgG secreted was measured by ELISA. This measurement was performed using a human anti-IgG antibody ELISA kit (Funakoshi).
- the horizontal axis represents the sample group, and the vertical axis represents the amount of IgG secreted (ng / mL).
- IgG is 1326 ng / mL
- the M7 administration group, the M9 administration group, the yk-7 administration group, the yk-8-3 administration group, the yk-8-1 administration group, the M11 administration group, the M12 administration group, the M14 administration group, and the M15 administration group It was found that IgG secretion was remarkably suppressed in the M16-administered group, the M18-administered group, and the M19-administered group. That is, the control group caused renal disorders, amyloidosis, and hyperviscosity syndrome due to IgG production, and the M7 administration group, the M9 administration group, the yk-7 administration group, the yk-8-3 administration group, and the yk-8-1 administration group.
- M11-administered group, M12-administered group, M14-administered group, M15-administered group, M16-administered group, M18-administered group, and M19-administered group can be said to have suppressed renal disorders, amyloidosis, and hyperviscosity syndrome.
- Example 22 Effect of suppressing the secretion of ⁇ chain of immunoglobulin free light chain by administration of each compound to KMS-28BM cells>
- ELISA enzyme-linked immunosorbent assay
- KMS-28BM cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control), and KMS-28BM cells were seeded in 75 cm 2 flasks, and after 4 hours of pre-culture, M7 is 0.05 ⁇ M, M9 is 0.01 ⁇ M, yk-7 is 0.5 ⁇ M, yk-8-3 is 0.05 ⁇ M, yk-8-1 is 50 ⁇ M, M11 is 0.5 ⁇ M, and M12 is 0.05 ⁇ M.
- M14 was added at a final concentration of 0.005 ⁇ M, M15 at 0.005 ⁇ M, M16 at 0.005 ⁇ M, M18 at 0.5 ⁇ M, and M19 at a final concentration of 0.5 ⁇ M under the conditions of 37 ° C. and 5% CO 2 . Incubated for 10 days. After culturing for 10 days, the culture supernatant was collected, and the amount of ⁇ chain secreted from the immunoglobulin free light chain was measured by ELISA. This measurement was performed using a human anti- ⁇ chain antibody ELISA kit (Funakoshi).
- the results are shown in FIG.
- the horizontal axis represents the sample group, and the vertical axis represents the amount of ⁇ chain secretion ( ⁇ g / L).
- IgG is 48 ⁇ g / L
- M14 administration group, M15 administration group, M16 administration group, M18 administration group, M19 administration group 2.1 ⁇ g / L, 3 ⁇ g / L, 2.3 ⁇ g / L, 1.3 ⁇ g / L, 35 ⁇ g / L, 1 respectively.
- the group, M11-administered group, M12-administered group, M14-administered group, M15-administered group, M16-administered group, M18-administered group, and M19-administered group suppressed renal disorders, amyloidosis, and hyperviscosity syndrome.
- Example 23 Effect of suppressing IL-6 secretion by administration of each compound to KMS-28BM cells> As a result of examining the secretory inhibitory effect of IL-6 by administration of each compound using KMS-28BM cells with Luminex, the secretory inhibitory effect of IL-6 was confirmed.
- KMS-28BM cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control), and KMS-28BM cells were seeded in 75 cm 2 flasks, and after 4 hours of pre-culture, M7 is 0.05 ⁇ M, M9 is 0.01 ⁇ M, yk-7 is 0.5 ⁇ M, yk-8-3 is 0.05 ⁇ M, yk-8-1 is 50 ⁇ M, M11 is 0.5 ⁇ M, and M12 is 0.05 ⁇ M.
- M14 was added at a final concentration of 0.005 ⁇ M, M15 at 0.005 ⁇ M, M16 at 0.005 ⁇ M, M18 at 0.5 ⁇ M, and M19 at a final concentration of 0.5 ⁇ M under the conditions of 37 ° C. and 5% CO 2 . Incubated for 10 days. After culturing for 10 days, the culture supernatant was collected, and the amount of IL-6 secreted as a bone destruction-related factor and a growth-promoting factor was measured by Luminex. This measurement was performed using a Human Magnetic Luminex Assay (R & D).
- the results are shown in FIG. 37.
- the horizontal axis represents the sample group, and the vertical axis represents the amount of IL-6 secreted (pg / mL). In Control, the amount of IL-6 secreted was 143 pg / mL.
- the IL-6 secretion amount was 12 pg / mL, 11 pg / mL, 16 pg / mL, 14 pg / mL, 84 pg / mL, 12 pg / mL, 14 pg / mL, 12 pg / mL, respectively. It was 14 pg / mL, 12 pg / mL, 11 pg / mL, and 22 pg / mL.
- the control group had bone lesions (bone destruction) due to IL-6 production, hypercalcemia associated with bone lesions, pathological fractures, spinal compression fractures, spinal compression symptoms associated with spinal compression fractures, and neurological symptoms associated with spinal compression symptoms.
- the administration group, M18 administration group, and M19 administration group are associated with bone lesions (bone destruction), hypercalcemia associated with bone lesions, pathological fractures, spinal compression fractures, spinal compression symptoms associated with spinal compression fractures, and spinal compression symptoms. It can be said that the neurological symptoms were suppressed.
- the target group promoted cell proliferation of multiple myeloma by autocrine associated with IL-6 production
- the 8-1 administration group, the M11 administration group, the M12 administration group, the M14 administration group, the M15 administration group, the M16 administration group, the M18 administration group, and the M19 administration group suppressed the cell proliferation of multiple myeloma.
- Example 24 IgG secretion inhibitory effect by administration of each compound in L363 cells> As a result of examining the IgG secretion inhibitory effect by administration of each compound using L363 cells by the enzyme-linked immunosorbent assay (ELISA), the IgG secretion inhibitory effect was confirmed.
- ELISA enzyme-linked immunosorbent assay
- L363 cells were seeded in 75 cm 2 flasks and cultured at 37 ° C. for 10 days under the condition of 5% CO 2 (Control), L363 cells were seeded in 75 cm 2 flasks, and after 4 hours pre-culture, M7 was 0. 1 ⁇ M, M9 is 0.05 ⁇ M, yk-7 is 0.1 ⁇ M, yk-8-3 is 0.1 ⁇ M, yk-8-1 is 50 ⁇ M, M11 is 0.1 ⁇ M, M12 is 0.01 ⁇ M, and M14 is 0.
- M15 was added to 0.005 ⁇ M
- M16 was added to 0.005 ⁇ M
- M18 was added to 1 ⁇ M
- M19 was added to a final concentration of 1 ⁇ M
- the cells were cultured at 37 ° C. and 5% CO 2 for 10 days. After culturing for 10 days, the culture supernatant was collected and the amount of IgG secreted was measured by ELISA. This measurement was performed using a human anti-IgG antibody ELISA kit (Funakoshi).
- the results are shown in Fig. 38.
- the horizontal axis represents the sample group, and the vertical axis represents the amount of IgG secreted (ng / mL).
- IgG is 2098 ng / mL
- the M7 administration group, the M9 administration group, the yk-7 administration group, the yk-8-3 administration group, the yk-8-1 administration group, the M11 administration group, the M12 administration group, the M14 administration group, and the M15 administration group It was found that IgG secretion was remarkably suppressed in the M16-administered group, the M18-administered group, and the M19-administered group. That is, the control group caused renal disorders, amyloidosis, and hyperviscosity syndrome due to IgG production, and the M7 administration group, the M9 administration group, the yk-7 administration group, the yk-8-3 administration group, and the yk-8-1 administration group.
- M11-administered group, M12-administered group, M14-administered group, M15-administered group, M16-administered group, M18-administered group, and M19-administered group can be said to have suppressed renal disorders, amyloidosis, and hyperviscosity syndrome.
- ⁇ Example 25 Effect of suppressing the secretion of ⁇ chain of immunoglobulin free light chain by administration of each compound to L363 cells>
- ELISA enzyme-linked immunosorbent assay
- L363 cells were seeded in 75 cm 2 flasks and cultured under the conditions of 37 ° C. and 5% CO 2 for 10 days (Control). L363 cells were seeded in 75 cm 2 flasks, and after 4 hours pre-culture, M7 was 0. 1 ⁇ M, M9 is 0.05 ⁇ M, yk-7 is 0.1 ⁇ M, yk-8-3 is 0.1 ⁇ M, yk-8-1 is 50 ⁇ M, M11 is 0.1 ⁇ M, M12 is 0.01 ⁇ M, and M14 is 0.
- M15 was added to 0.005 ⁇ M
- M16 was added to 0.005 ⁇ M
- M18 was added to 1 ⁇ M
- M19 was added to a final concentration of 1 ⁇ M
- the cells were cultured at 37 ° C. and 5% CO 2 for 10 days. After culturing for 10 days, the culture supernatant was collected, and the amount of ⁇ chain secreted from the immunoglobulin free light chain was measured by ELISA. This measurement was performed using a human anti- ⁇ chain antibody ELISA kit (Funakoshi).
- the results are shown in Fig. 39.
- the horizontal axis represents the sample group, and the vertical axis represents the amount of ⁇ chain secretion ( ⁇ g / L).
- IgG is 145 ⁇ g / L
- the group, the M14-administered group, the M15-administered group, the M16-administered group, the M18-administered group, and the M19-administered group suppressed renal disorders, amyloidosis, and hyperviscosity syndrome.
- Example 26 Suppressive effect of MIP-1 ⁇ secretion by administration of each compound to L363 cells> As a result of examining the secretory inhibitory effect of MIP-1 ⁇ by administration of each compound using L363 cells with Luminex, the secretory inhibitory effect of MIP-1 ⁇ was confirmed.
- L363 cells were seeded in 75 cm 2 flasks and cultured at 37 ° C. for 10 days under the condition of 5% CO 2 (Control), L363 cells were seeded in 75 cm 2 flasks, and after 4 hours pre-culture, M7 was 0. 1 ⁇ M, M9 is 0.05 ⁇ M, yk-7 is 0.1 ⁇ M, yk-8-3 is 0.1 ⁇ M, yk-8-1 is 50 ⁇ M, M11 is 0.1 ⁇ M, M12 is 0.01 ⁇ M, and M14 is 0.
- M15 was added to 0.005 ⁇ M
- M16 was added to 0.005 ⁇ M
- M18 was added to 1 ⁇ M
- M19 was added to a final concentration of 1 ⁇ M
- the cells were cultured at 37 ° C. and 5% CO 2 for 10 days. After culturing for 10 days, the culture supernatant was collected, and the amount of MIP-1 ⁇ , which is a bone destruction-related factor and a growth promoting factor, was measured by Luminex. This measurement was performed using a Human Magnetic Luminex Assay (R & D).
- Fig. 40 The results are shown in Fig. 40.
- the horizontal axis represents the sample group, and the vertical axis represents the amount of MIP-1 ⁇ secreted (pg / mL). In Control, the amount of MIP-1 ⁇ secreted was 266 pg / mL.
- the amount of MIP-1 ⁇ secreted was 9 pg / mL, 3 pg / mL, 17 pg / mL, 2 pg / mL, 179 pg / mL, 6 pg / mL, 2 pg / mL, 2 pg / mL, respectively. It was 30 pg / mL, 2 pg / mL, 3 pg / mL, and 42 pg / mL.
- the M7 administration group, the M9 administration group, the yk-7 administration group, the yk-8-3 administration group, the yk-8-1 administration group, the M11 administration group, the M12 administration group, the M14 administration group, and the M15 administration group It was found that MIP-1 ⁇ secretion was remarkably suppressed in the M16-administered group, the M18-administered group, and the M19-administered group.
- bone lesions (bone destruction) due to MIP-1 ⁇ production hypercalcemia associated with bone lesions, pathological fractures, spinal compression fractures, spinal compression symptoms associated with spinal compression fractures, and neurological symptoms associated with spinal compression symptoms
- M7 administration group, M9 administration group, yk-7 administration group, yk-8-3 administration group, yk-8-1 administration group M11 administration group, M12 administration group, M14 administration group, M15 administration group, M16
- the administration group, M18 administration group, and M19 administration group are associated with bone lesions (bone destruction), hypercalcemia associated with bone lesions, pathological fractures, spinal compression fractures, spinal compression symptoms associated with spinal compression fractures, and spinal compression symptoms. It can be said that the neurological symptoms were suppressed.
- the target group promoted cell proliferation of multiple myeloma by autocrine associated with MIP-1 ⁇ production
- the 8-1 administration group, the M11 administration group, the M12 administration group, the M14 administration group, the M15 administration group, the M16 administration group, the M18 administration group, and the M19 administration group suppressed the cell proliferation of multiple myeloma.
- Example 27 Tumor growth inhibitory effect by M9 administration in vivo on L363 cells> As a result of transplanting L363 cells into NOD / ShiJic-sidJcl mice and examining the tumor growth inhibitory effect when M9 was orally administered, a remarkable tumor growth inhibitory effect was observed.
- L363 cells were transplanted into NOD / ShiJic-sidJcl mice, and the time when the average tumor volume exceeded 100 mm 3 was taken as the 0th day, and M9 was orally administered to the mice at 100 mg / kg every day to obtain the tumor volume on the 24th day. It was measured.
- the group to which only L363 cells were transplanted is called a target group, and the group to which M9 was administered is called an M9 administration group.
- Each group consisted of 5 animals.
- Fig. 41 The results are shown in Fig. 41.
- the horizontal axis shows the drug treatment and the vertical axis shows the tumor volume (percentage to the target group).
- the white bar indicates the target group (indicated as "Control”).
- the black bar indicates the M9 administration group (indicated as "100 mg / kg M9").
- “*" was shown for those with a significant difference (P ⁇ 0.01) with respect to the target group.
- the M9 administration group showed marked suppression of tumor growth. That is, the M9-administered group significantly suppressed tumor growth than the target group.
- FIG. 42 shows a photograph of the tumor on the 26th day after the start of medication.
- FIG. 42 (a) shows a photograph of the tumor of one mouse in the subject group
- FIG. 42 (b) shows a photograph of the tumor of one mouse in the M9-administered group.
- the target group of FIG. 42 (a) tumor growth is remarkably observed.
- the M9-administered group shown in FIG. 42 (b) a remarkable decrease in volume was observed as compared with the target group. As described above, it was found that the M9-administered group markedly suppressed tumor growth.
- Example 28 Tumor growth inhibitory effect by administration of M9 and M14 in vivo on Raji cells> As a result of transplanting Raji cells into NOD / ShiJic-sidJcl mice and examining the tumor growth inhibitory effect when M9 and M14 were orally administered, a remarkable tumor growth inhibitory effect was observed.
- Raji cells were transplanted into NOD / ShiJic-sidJcl mice, and the time when the average tumor volume exceeded 100 mm 3 was taken as the 0th day, and M9 was orally administered to the mice at 50 mg / kg and M14 at 50 mg / kg every day. The tumor volume on the day was measured.
- the group to which Raji cells are simply transplanted is called a target group
- the group to which M9 is administered is called an M9-administered group
- the group to which M14 is administered is called an M14-administered group.
- Each group consisted of 5 animals.
- the horizontal axis shows the drug treatment and the vertical axis shows the tumor volume (percentage to the target group).
- the white bar indicates the target group (indicated as "Control”).
- the black bar indicates the M9 administration group (indicated as "50 mg / kg M9"), and the vertical line indicates the M14 administration group (indicated as "50 mg / kg M14").
- “*” was shown for those with a significant difference (P ⁇ 0.01) with respect to the target group.
- the M9 administration group black bar
- the M14 administration group vertical line bar
- FIG. 44 shows a photograph of the tumor on the 21st day after the start of medication.
- FIG. 44 (a) shows a photograph of a target group
- FIG. 44 (b) shows a photograph of a tumor of one mouse in the M9-administered group
- FIG. 44 (c) shows a photograph of one mouse in the M14-administered group.
- the target group of FIG. 44 (a) tumor growth is remarkably observed.
- the M9-administered group of FIG. 44 (b) and the M14-administered group of FIG. 44 (c) a remarkable decrease in volume was observed as compared with the target group. As described above, it was found that the M9-administered group and the M14-administered group remarkably suppressed tumor growth.
- the composition for improving malignant tumor disease includes not only multiple myeloma but also lymphoma, lymphoma, malignant lymphoma (MALT lymphoma, DLBCL, Berkit lymphoma, Hodgkin lymphoma, adult T cell leukemia, peripheral T lymphoma, etc.). ), Voltezomib-resistant multiple myeloma, rituximab-resistant malignant lymphoma, pancreatic cancer, breast cancer, malignant melanoma, lung cancer, liver cancer, gastric cancer, colon cancer, head and neck tumor, glioma, renal cancer, ovarian cancer and uterine body cancer.
- CRAB renal disorder, amyloidosis, hyperviscosity syndrome, bone lesion (bone destruction), hypercalcemia associated with bone lesion, pathological fracture, spinal compression fracture, spinal compression fracture associated with multiple myeloma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
マンギフェリン(4.21g,10.0mmol)、無水プロピオン酸(19.2mL,149mmol)、DMAP(122mg,1mmol)および乾燥ピリジン(60mL)を100℃で24時間加熱した。反応液を氷水(600mL)に注加し、酢酸エチルで抽出した。酢酸エチル層を氷冷した10%硫酸、飽和炭酸水素ナトリウム水溶液および飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー(n-ヘキサン/酢酸エチル=1/1)を用いて精製し、標題化合物(7.19g,83%)を無色固体として得た。
IR (KBr): 1774, 1755, 1667, 1620, 1458, 1354, 1273, 1157, 1114, 1083 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 ℃) δ: 0.71-0.77/0.93-0.97 (each 3H, m, COCH2CH3), 0.98-1.02/1.12-1.16/1.19-1.28 (each 6H, m, COCH2CH3), 1.92-2.01 (2H, m, COCH2CH3), 2.17-2.32 (6H, m, COCH2CH3), 2.60-2.94 (8H, m, COCH2CH3), 3.86-3.92 (1H, m, H-6’a), 4.21-4.30 (2H, m, H-5’ and H-6’b), 5.01-5.06 (1H, m, H-4’), 5.10-5.20 (1H, m, H-1’), 5.45-5.53 (2H, m, H-2’ and H-3’), 7.51/7.53 (1H, each s, H-4), 7.68/7.69 (1H, each s, H-5), 7.97/7.98 (1H, each s, H-8). 13C NMR (200 MHz, DMSO-d6 25 ℃) δ: 8.64/8.75/8.77/8.91/8.94/8.96/9.00/9.13/9.16 (COCH2CH3), 26.58/26.63/26.7/26.8/26.89/26.94/27.0/27.1/27.32/27.34 (COCH2CH3), 62.1/62.2 (C6’), 68.18/68.20 (C4’), 69.6/70.0 (C2’), 70.8/71.3 (C1’), 73.5/73.6 (C3’), 75.0/75.1 (C5’), 110.2/111.8 (C4), 111.6/112.7 (C9a), 113.2/113.3 (C5), 118.8/118.9 (C2), 119.6/119.7 (C8a), 120.3/120.4 (C8), 139.5/139.6 (C7), 147.9 (C6), 149.1/150.9 (C1), 152.47/152.51 (C8b), 153.4/154.8 (C4a), 156.5/156.8 (C3), 170.9/171.04/171.06/171.09/171.67/171.72/171.9/172.4/172.6/172.7/173.18/173.22/173.51/173.54 (COCH2CH3), 173.1 (C9). HRMS (ESI) m/z: [M+Na]+ Calcd for C43H50O19Na 893.2839; Found 893.2853.
M7の製造方法で、無水プロピオン酸を無水酪酸に置き換えたほかは、M7の合成方法に従い合成した。収率は81%であった。
無色固体: IR (KBr): 1775, 1751, 1665, 1618, 1458, 1157, 1092 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 ℃) δ: 0.52-1.11 (24H, m, COCH2CH2CH3), 1.20-1.97 (16H, m, COCH2CH2CH3), 2.14-2.88 (16H, m, COCH2CH2CH3), 3.88-3.94 (1H, m, H-6’a), 4.16-4.25 (2H, m, H-5’ and H-6’b), 5.02-5.06 (1H, m, H-4’), 5.06-5.12 (1H, m, H-1’), 5.45-5.52 (1H, m, H-3’), 5.54-5.65 (1H, m, H-2’), 7.50/7.53 (1H, each s, H-4), 7.68/7.69 (1H, each s, H-5), 7.95/7.96 (1H, each s, H-8). 13C NMR (200 MHz, DMSO-d6 25 ℃) δ: 13.1/13.41/13.45/13.48/13.51/13.58/13.64/13.8 (COCH2CH2CH3), 17.5/17.62/17.66/17.72/17.76/17.83/17.88/17.90 (COCH2CH2CH3), 34.9/35.09/35.15/35.17/35.19/35.31/35.33/35.4/35.68/35.73 (COCH2CH2CH3), 62.0/62.2 (C6’), 68.2/68.3 (C4’), 69.3/69.8 (C2’), 70.9/71.3 (C1’), 73.36/73.43 (C3’), 75.1/75.2 (C5’), 110.2/111.6 (C4), 111.6/112.6 (C9a), 113.3/113.4 (C5), 118.7/118.8 (C2), 119.6/119.7 (C8a), 120.35/120.40 (C8), 139.5 (C7), 147.82/147.85 (C6), 149.1/150.8 (C1), 152.46/152.49 (C8b), 153.4/154.7 (C4a), 156.6/156.8 (C3), 169.9/170.14/170.17/170.18/170.7/170.8/171.0/171.4/171.6/171.8/172.0/172.1/172.5/172.6 (COCH2CH3), 173.1 (C9). HRMS (ESI) m/z: [M+Na]+ Calcd for C51H67O19Na 1005.4091; Found 1005.4092.
M7の製造方法で、無水プロピオン酸を無水吉草酸に置き換えた他は、M7の合成方法に従い合成した。収率は83%であった。
無色固体: IR (KBr): 1771, 1747, 1668, 1614, 1456, 1157, 1092 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 ℃) δ: 0.52-1.82 (56H, m, COCH2CH2CH2CH3), 1.88-2.30/2.56-2.94 (16H, each m, COCH2CH2CH2CH3), 3.89-3.95 (1H, m, H-6’a), 4.13-4.23 (2H, m, H-5’ and H-6’b), 5.02-5.06 (1H, m, H-4’), 5.06-5.12 (1H, m, H-1’), 5.44-5.52 (1H, m, H-3’), 5.56-5.65 (1H, m, H-2’), 7.49/7.53 (1H, each s, H-4), 7.67/7.68 (1H, each s, H-5), 7.95/7.96 (1H, each s, H-8). 13C NMR (200 MHz, DMSO-d6 25 ℃) δ: 13.4/13.59/13.64/13.7/13.77/13.80/13.9 (COCH2CH2CH2CH3), 21.4/21.66/21.68/21.72/21.74/21.86/21.88/22.0 (COCH2CH2CH2CH3), 26.1/26.25/26.29/26.36/26.45/26.47/26.51/26.52 (COCH2CH2CH2CH3), 32.8/33.0/33.09/33.14/33.21/33.23/33.7/33.8 (COCH2CH2CH2CH3), 62.1/62.3 (C6’), 68.29/68.32 (C4’), 69.3/69.8 (C2’), 70.8/71.3 (C1’), 73.4/73.5 (C3’), 75.1/75.2 (C5’), 110.2/111.6 (C4), 111.6/112.6 (C9a), 113.28/113.31 (C5), 118.7/118.8 (C2), 119.6/119.7 (C8a), 120.3/120.4 (C8), 139.5 (C7), 147.82/147.85 (C6), 149.1/150.9 (C1), 152.43/152.47 (C8b), 153.4/154.7 (C4a), 156.6/156.8 (C3), 169.9/170.1/170.3/170.86/170.94/171.1/171.5/171.7/171.9/172.12/172.14/172.66/172.69 (COCH2CH3), 173.1 (C9). HRMS (ESI) m/z: [M+Na]+ Calcd for C59H82O19Na 1117.5343; Found 117.5344.
1,3,2’,3’,4’,6,6’,7-オクタ-O-ブチリルマンギフェリン(M11)(5.06g, 5.68mmol)、酢酸アンモニウム (6.7g, 87.0mmol)、メタノール (160mL) および水 (20mL) の混合溶液を室温で6時間撹拌した。反応液から減圧濃縮によりメタノールを留去した後、残渣を酢酸エチル (100mL) で希釈した。その混合物を、水および飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー [CHCl3/CH3OH (20:1)] を用いて精製し、標題化合物 (3.89g 93%) を淡黄色固体として得た。
淡かっ色固体: IR (KBr): 3385, 1751, 1624, 1458, 1288, 1188, 1099 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 ℃) δ: 0.48-1.09 (15H, m, COCH2CH2CH3), 1.18-1.83 (10H, m, COCH2CH2CH3), 1.89-2.86 (10H, m, COCH2CH2CH3), 3.87 (0.5H, dd-like, J = ca. 12.6, 1.6, H-6a’), 4.02-4.11 (2H, br m, , H-5, H-5’, H-6a’, H-6b’), 4.16 (0.5H, dd, J = 12.6, 4.8, H-6b’), 4.90 (0.5H, d, J = 9.6, H-1’), 5.01 (0.5H, dd, J = 9.6, 9.6, H-4’), 5.02 (0.5H, dd, J = 9.6, 9.6, H-4’), 5.15 (0.5H, d, J = 10.4, H-1’), 5.35 (0.5H, dd, J = 9.6, 9.6, H-3’), 5.37 (0.5H, br dd-like, J = ca. 9.6, 9.6, H-3’), 5.54 (0.5H, dd, J = 10.4, 9.6, H-2’), 5.88 (0.5H, br dd-like, J = ca. 9.6, 9.6, H-2’), 6.72/6.74 (each 0.5H, s, H-4), 6.797/6.803 (each 0.5H, s, H-5), 7.29/7.30 (each 0.5H, s, H-8), 9.67/10.5/11.2 (each 1H, br s, OH). 13C NMR (200 MHz, DMSO-d6, 25 ℃) δ: 13.1/13.4/13.50/13.54/13.6/13.7/13.9 (COCH2CH2CH3), 17.7/17.90/17.93/17.96/18.02 (COCH2CH2CH3), 35.1/35.2/35.3/35.37/35.41/35.46/35.50/35.54/35.9 (COCH2CH2CH3), 62.0/62.4 (C-6’), 68.2/68.4 (C-4’), 68.5/70.3 (C-2’), 71.1/71.2 (C-1’), 73.7/74.0 (C-3’), 74.9/75.3 (C-5’), 99.7/100.8 (C-4), 102.52/102.54 (C-5), 106.6/107.8 (C-9a), 109.1 (C-8), 113.2/113.4 (C-2), 114.06/114.08 (C-8a), 143.9 (C-7), 149.8/149.9 (C-6, C-1), 151.3 (C-1), 153.3 (C-8b), 157.6/157.7 (C-4a), 160.9/162.3 (C-3), 170.3/171.1/171.2/171.5/171.9/172.2/172.6 (COCH2CH3) 172.7 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C39H47O16 771.2859; Found 771.2858.
M12の合成方法において、1,3,2’,3’,4’,6,6’,7-オクタ-O-ブチリルマンギフェリン(M11)に変えて、1,3,2’,3’,4’,6,6’,7-オクタ-O-バレリルマンギフェリン(yk-8-1)を出発材とした他は、M12の合成方法に従って合成した。収率は90%であった。
淡かっ色固体: IR (KBr): 3399, 1751, 1618, 1458, 1290, 1167, 1097 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 ℃) δ: 0.56-1.82 (35H, m, COCH2CH2CH2CH3), 2.12-2.32 (6H, m, COCH2CH2CH2CH3), 2.58-2.87 (4H, m, COCH2CH2CH2CH3), 3.88 (0.5H, dd-like, J = ca. 12.6, 1.6, H-6a’), 4.02-4.10 (2H, br m, H-5, H-5’, H-6a’, H-6b’), 4.12 (0.5H, dd, J = 12.6, 5.0, H-6b’), 4.90 (0.5H, d, J = 9.9, H-1’), 5.00 (0.5H, dd, J = 9.6, 9.6, H-4’), 5.03 (0.5H, dd, J = 9.7, 9.7, H-4’), 5.15 (0.5H, d, J = 10.0, H-1’), 5.35 (0.5H, dd, J = 9.6, 9.6, H-3’), 5.37 (0.5H, br dd-like, J = ca. 9.7, 9.7, H-3’), 5.57 (0.5H, dd, J = 10.0, 9.6, H-2’), 5.87 (0.5H, br dd-like, J = ca. 9.9, 9.7, H-2’), 6.71/6.75 (each 0.5H, s, H-4), 6.796/6.804 (each 0.5H, s, H-5), 7.29/7.30 (each 0.5H, s, H-8), 9.61/10.5 (each 1H, br s, OH), 11.2/11.4 (each 0.5H, br s, OH). 13C NMR (200 MHz, DMSO-d6, 25 ℃) δ: 13.5/13.62/13.67/13.69/13.9 (COCH2CH2CH2CH3), 21.3/21.4/21.68/21.69/21.7/21.9/22.1 (COCH2CH2CH2CH3), 26.3/26.45/26.48/26.50/26.52/26.55/26.57 (COCH2CH2CH2CH3), 33.0/33.1/33.16/33.21/33.27/33.34/33.9 (COCH2CH2CH2CH3), 62.1/62.4 (C-6’), 68.3/68.4 (C-4’), 68.4/70.2 (C-2’), 71.0/71.2 (C-1’), 73.7/74.0 (C-3’), 74.9/75.2 (C-5’), 99.6/100.8 (C-4), 102.46/102.49 (C-5), 106.65/107.71 (C-9a), 109.1 (C-8), 113.1/113.2 (C-2), 114.0 (C-8a), 143.8 (C-7), 149.77/149.80 (C-6, C-1), 151.3 (C-1), 153.22/153.24 (C-8b), 157.6/157.7 (C-4a), 160.8/162.2 (C-3), 170.2/171.1/171.3/171.6/171.97/172.00/172.2/172.69/172.73 (COCH2CH3) 172.6 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C44H57O16 841.3641; Found 841.3640.
1,2’,3’,4’,6-ペンタ-O-プロピオニルマンギフェリン(M8)(3.88g,5.52mmol)、N,N-ジメチルトリメチレンジアミン(3.47mL,27.6mmol)およびDMSO(40mL)の混合物を室温で1時間撹拌した。反応液を氷水(500mL)に注加し、ジエチルエーテルおよびヘキサンの混合溶液(3/1)で抽出した。有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー[CHCl3/CH3OH(20:1)]を用いて精製し、標題化合物(3.08g,86%)を淡黄色固体として得た。
IR (KBr): 3399 1751, 1618, 1475, 1292, 1190, 1084 cm-1. 1H NMR (800 MHz, DMSO-d6, 60 ℃) δ: 0.74/0.97/1.02/1.03 (each 3H, t, J = 7.6, COCH2CH3), 1.95/1.98 (each 1H, dq, J = 16.5, 7.6, COCH2CH3), 2.18 (2H, q, J = 7.6, COCH2CH3), 2.22-2.34 (4H, m, COCH2CH3), 3.99 (1H, ddd-like, J = 9.8, 4.5, 2.5, H-5’), 4.10 (1H, dd, J = 12.5, 2.5, H-6a’), 4.12 (1H, dd, J = 12.5, 4.5, H-6b’), 5.06 (1H, dd, J = 9.8, 9.8, H-4’), 5.10 (1H, d, J = 10.0, H-1’), 5.31 (1H, dd, J = 9.8, 9.5, H-3’), 5.85 (1H, br dd, J = 10.0, 9.5, H-2’), 6.35 (1H, s, H-4), 6.85 (1H, s, H-4), 7.34 (1H, s, H-8), 9.0-11.0 (3H, br, OH), 13.9 (1H, s, OH). 13C NMR (200 MHz, DMSO-d6, 60 ℃) δ: 8.71/8.79/8.82 (COCH2CH3), 26.72/26.73/ 26.77/26.83 (COCH2CH3), 62.0 (C-6’), 68.3 (C-4’), 69.1 (C-2’), 70.4 (C-1’), 74.2 (C-3’), 75.0 (C-5’), 93.3 (C-4), 101.0 (C-9a), 102.6 (C-5), 104.2 (C-2), 108.2 (C-8), 111.7 (C-8a), 143.8 (C-7), 150.8 (C-6), 154.2 (C-8b), 156.8 (C-4a), 161.9 (C-1), 163.6 (C-3), 171.9/172.5/172.7/173.1 (COCH2CH3) 179.0 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C31H33O15 645.1814; Found 645.1817.
M9の合成方法において、1,3,2’,3’,4’,6,6’,7-オクタ-O-プロピオニルマンギフェリン(M8)に変えて、1,2’,3’,4’,6-ペンタ-O-ブチリルマンギフェリン(M12)を出発材とした他は、M9の合成方法に従って合成した。収率は84%であった。
淡黄色固体:IR (KBr): 3399 1751, 1618, 1474, 1292, 1188, 1085 cm-1. 1H NMR (800 MHz, DMSO-d6, 60 ℃) δ: 0.50 (3H, br, t-like J = ca. 7.0, COCH2CH2CH3), 0.83/0.871/0.872 (each 3H, t, J = 7.4, COCH2CH2CH3), 1.18-1.30/1.44-1.49 (each 2H, m, COCH2CH2CH3), 1.50-1.56 (6H, m, COCH2CH2CH3), 1.93 (2H, t, J = 7.0, COCH2CH2CH3), 2.15 (2H, t, J = 7.2, COCH2CH2CH3), 2.22-2.31 (4H, m, COCH2CH2CH3), 3.98 (1H, ddd-like, J = 9.8, 4.6, 2.5, H-5’), 4.09 (1H, dd, J = 12.5, 4.6, H-6a’), 4.11 (1H, dd, J = 12.5, 2.5, H-6b’), 5.06 (1H, dd, J = 9.8, 9.8, H-4’), 5.09 (1H, d, J = 10.0, H-1’), 5.31 (1H, dd, J = 9.8, 9.5, H-3’), 5.85 (1H, br dd, J = 10.0, 9.5, H-2’), 6.34 (1H, s, H-4), 6.85 (1H, s, H-4), 7.38 (1H, s, H-8), 8.9-11.5 (3H, br, OH), 13.9 (1H, s, OH). 13C NMR (200 MHz, DMSO-d6, 60 ℃) δ: 12.6/13.13/13.16/13.22 (COCH2CH2CH3), 17.62/17.64/17.66 (COCH2CH2CH3), 35.16/35.23/35.26/35.31 (COCH2CH2CH3), 61.9 (C-6’), 68.3 (C-4’), 69.0 (C-2’), 70.4 (C-1’), 74.1 (C-3’), 75.0 (C-5’), 93.3 (C-4), 101.1 (C-9a), 102.6 (C-5), 104.2 (C-2), 108.2 (C-8), 111.7 (C-8a), 143.8 (C-7), 150.8 (C-6), 154.2 (C-8b), 156.8 (C-4a), 162.1 (C-1), 163.7 (C-3), 170.9/171.6/171.7/172.3 (COCH2CH3) 179.0 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C35H41O15 701.2440; Found 701.2440.
M9の合成方法において、1,3,2’,3’,4’,6,6’,7-オクタ-O-プロピオニルマンギフェリン(M8)に変えて、1,2’,3’,4’,6-ペンタ-O-バレリルマンギフェリン(yk-8-3)を出発材とした他は、M9の合成方法に従って合成した。収率は82%であった。
淡黄色固体:IR (KBr): 3393 1751, 1618, 1474, 1292, 1184, 1091 cm-1. 1H NMR (800 MHz, DMSO-d6, 60 ℃) δ: 0.54 (3H, br s-like, COCH2CH2CH2CH3), 0.82/0.84/0.86 (each 3H, t, J = 7.4, COCH2CH2CH2CH3), 0.85-0.94 (2H, m, COCH2CH2CH2CH3), 1.10-1.52 (14H, m, COCH2CH2CH2CH3), 1.95 (2H, t, J = 7.2, COCH2CH2CH2CH3), 2.16 (2H, t, J = 7.3, COCH2CH2CH2CH3), 2.21-2.32 (4H, m, COCH2CH2CH2CH3), 3.98 (1H, ddd-like, J = 9.8, 4.5, 2.5, H-5’), 4.08 (1H, dd, J = 12.5, 4.5, H-6a’), 4.10 (1H, dd, J = 12.5, 2.5, H-6b’), 5.05 (1H, dd, J = 9.8, 9.8, H-4’), 5.08 (1H, d, J = 10.0, H-1’), 5.31 (1H, dd, J = 9.8, 9.5, H-3’), 5.85 (1H, br dd, J = 10.0, 9.5, H-2’), 6.34 (1H, s, H-4), 6.85 (1H, s, H-4), 7.38 (1H, s, H-8), 9.0-11.5 (3H, br, OH), 13.9 (1H, s, OH). 13C NMR (200 MHz, DMSO-d6, 60 ℃) δ: 13.0/13.23/13.28/13.31 (COCH2CH2CH2CH3), 21.0/21.37/21.40 (COCH2CH2CH2CH3), 26.27/26.30/26.34 (COCH2CH2CH2CH3), 33.00/33.02/33.03/33.08 (COCH2CH2CH2CH3), 62.0 (C-6’), 68.4 (C-4’), 68.9 (C-2’), 70.4 (C-1’), 74.1 (C-3’), 75.0 (C-5’), 93.3 (C-4), 101.0 (C-9a), 102.6 (C-5), 104.2 (C-2), 108.1 (C-8), 111.7 (C-8a), 143.8 (C-7), 150.8 (C-6), 154.1 (C-8b), 156.8 (C-4a), 161.7 (C-1), 163.7 (C-3), 171.0/171.7/171.9/172.4 (COCH2CH3) 179.0 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C39H49O15 757.3066; Found 757.3060.
マンギフェリン(500mg,1.18mmol)、無水ピバル酢酸(4.79mL,23.7mmol)、4-ジメチルアミノピリジン(15mg,0.12mmol)および乾燥ピリジン(10mL)を100℃で2週間加熱した。反応液を氷水(50mL)に注加し、酢酸エチルで抽出した。酢酸エチル層を氷冷した10%硫酸、飽和炭酸水素ナトリウム水溶液および飽和食塩水で順次洗浄した。洗浄した酢酸エチル層を無水硫酸ナトリウムで乾燥後、ろ過、濃縮し、淡黄色油状物質(1.65g)を得た。得られた油状物質、N,N-ジメチルトリメチレンジアミン(1.03mL,8.27mmol)およびジメチルスルホキシド(30mL)の混合物を50℃で2時間撹拌した。反応液を氷水(50mL)に注加し、ジエチルエーテルおよびヘキサンの混合溶液(3/1)で抽出した。有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー(CHCl3/MeOH)を用いて精製し、標題化合物(948mg,1.25mmol,94%)を淡黄色固体として得た。
淡黄色固体:IR (KBr): 3387, 2974, 1746, 1651, 1618, 1481, 1290, 1173, 1144 cm-1; 1H-NMR (800 MHz, DMSO-d6, 60℃) δ: 0.81 / 1.05 / 1.11 / 1.16 (each 9H, s, COCH(CH3)3), 3.99-4.04 (2H, br-m, H-5’ and H-6’a), 4.16 (1H, d, J = 12.0 Hz, H-6’b), 5.10 (1H, d, J = 10.4 Hz, H-1’), 5.17 (1H, t, J = 9.6 Hz, H-4’), 5.33 (1H, t, J = 9.6 Hz, H-3’), 5.85 (1H, br, H-2’), 6.35 (1H,s, H-4), 6.84 (1H, s、H-5), 7.38 (1H, s, H-8); 13C-NMR (200 MHz, DMSO-d6, 60℃)δ: 26.9/27.2/27.32/27.36 [COCH(CH3)3], 38.5/38.70/38.79/38.9 (COCH(CH3)3), 62.0 (C-6’), 68.2 (C-4’), 69.5 (C-2’), 71.1 (C-1’), 74.7 (C-3’), 75.9 (C-5’), 94.2 8C-4), 103.3 (C-5), 104.8 (C-9a), 108.8 (C-8), 112.3 (C-2), 114.5 (C-8a), 144.5 (C-7), 151.4 (C-6), 153.6 (C-1), 154.8 (C-8b), 157.4 (C-4a), 162.5 (C-3), 176.2/176.3/176.9/177.5 [COCH(CH3)3]; HRMS (ESI) m/z: [M-H]- Calcd for C39H49O15 757.3066; Found 757.3037.
2’,3’-ジ-O-ブチルマンギフェリン(540mg,1.01mmol)、無水酪酸(2.48mL,15.2mmol)、4-ジメチルアミノピリジン(12mg,0.10mmol)および乾燥ピリジン(20mL)を80℃で15時間撹拌した。反応液を氷水に注加し、酢酸エチルで抽出した。酢酸エチル層を氷冷した10%硫酸、飽和炭酸水素ナトリウム水溶液および飽和食塩水で順次洗浄した。洗浄した酢酸エチル層を無水硫酸ナトリウムで乾燥後、ろ過、濃縮し、淡黄色液体(1.09g)を得た。得られた淡黄色液体、N,N-ジメチルトリメチレンジアミン(0.63mL,5.05mmol)およびジメチルスルホキシド(10mL)を50℃で3時間撹拌した。反応液を氷水(50mL)に注加し、ジエチルエーテルおよびヘキサンの混合溶液(3/1)で抽出した。有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー(CHCl3/MeOH)を用いて精製し、標題化合物(589mg,0.87mmol,86%)を淡黄色固体として得た。
淡黄色固体:IR(KBr):3354, 2960, 2934, 2874, 1748, 1616, 1476, 1293, 1188, 1084 cm-1. 1H-NMR (800 MHz, CDCl3) δ: 0.57/0.95 (each 3H, t, J = 7.6 Hz, COCH2CH2CH3), 0.87/0.98 (each 3H, t, J = 7.3 Hz, OCH2CH2CH2CH3), 1.10/1.18/1.19/1.26 (each 1H, sext, J = 7.3 Hz, OCH2CH2CH2CH3), 1.27-1.34/ 2.14-1.53 (each 2H, m, OCH2CH2CH2CH3) , 1.68 (4H, sext, J = 7.6 Hz, COCH2CH2CH3×2), 2.34/2.37 (each 2H, t, J = 7.6 Hz, COCH2CH2CH3), 3.05/3.46/3.58/3.80 (each 1H, td, J = 6.1, 9.2 Hz, OCH2CH2CH2CH3), 3.56 (1H, t, J = 9.2 Hz, H-2’), 3.62 (1H, br, H-4’), 3.82 (1H, td, J = 9.2, 4.0 Hz, H-5’), 4.23/4.26 (each 1H, dd, J = 12.8, 4.0 Hz, H-6’),5.09 (1H, d, J = 9.2 Hz, H-1’), 5.16 (1H, t, J = 9.2 Hz, H-3’), 6.39 (1H, s, H-4), 6.81 (1H, s, H-5), 7.59 (1H, s, H-8), 7.28/7.94/8.38/13.4 (each 1H, s, OH); 13C-NMR (200 MHz, CDCl3) δ:13.56/13.61 cm-1; (COCH2CH2CH3), 13.67/13.89 (OCH2CH2CH2CH3), 18.2/18.3 (COCH2CH2CH3), 18.8/19.2 (OCH2CH2CH2CH3), 31.9/32.4 (OCH2CH2CH2CH3), 35.9/36.1 (COCH2CH2CH3), 61.9 (C-6’), 69.2 (C-3’), 73.1/73.5 (OCH2CH2CH2CH3), 74.3 (C-1’), 76.6 (C-5’), 81.1 (C-4’), 83.4 (C-2’), 95.5 (C-4), 102.2 (C-9a), 102.8 (C-5), 105.2 (C-2), 108.3 (C-8), 113.0 (C-8a), 141.8 (C-7), 152.2 (C-8b), 152.7 (C-6), 157.5 (C-4a), 160.5 (C-1), 163.3 (C-3), 172.3/173.7 (COCH2CH2CH3), 179.9 (C-9); HRMS (ESI) m/z: [M+Na]+ Calcd for C35H46O13Na 697.2831; Found 697.2835.
1-(2-ヒドロキシエトキシ)-3,6,7-トリス(メトキシメトキシ)-9H-キサンテン-9-オン(100mg,0.23mmol)、10%塩酸(0.5mL)およびメタノール(5.0mL)の混合物を80℃で5時間加熱した。反応液内の沈殿物をろ過して得た後、メタノールで洗浄し、標題化合物(60.7mg,0.20mmol,87%)を淡黄色固体として得た。
淡黄色固体:IR(KBr): 3470, 3205, 3066, 2978, 2878, 1777, 1697, 1562, 1404, 1354, 1298, 1238, 1122 cm-1; 1H-NMR (800 MHz, DMSO-d6 ) δ: 3.75 (2H, t, J = 5.2 Hz, OCH2CH2OH), 4.05 (2H, t, J = 5.2 Hz, OCH2CH2OH), 6.35 (1H, d, 2.2 Hz, H-2), 6.38 (1H, d, 2.2 Hz, H-4), 6.75 (1H, s, H-5), 7.34 (1H, s, H-8), 9.50/10.26/10.65 (each 1H, s, phenolic OH); 13C-NMR (200 MHz, DMSO-d6) δ: 59.8 (OCH2CH2OH), 71.5 (OCH2CH2OH), 95.7 (C-4), 97.9 (C-2), 102.5 (C-5), 105.8 (C-9a), 109.6 (C-8), 115.2 (C-8a), 143.6 (C-7), 149.7 (C-8b), 152.7 (C-6), 159.3 (C-4a), 161.4 (C-1), 163.1 (C-3), 173.5 (C-9); HRMS (ESI) m/z: [M-H]- Calcd for C15H12O7 304.0583; Found 304.0579.
1-ヒドロキシ-3,6,7-トリス(メトキシメトキシ)-9H-キサンテン-9-オン(70mg,0.18mmol)、臭化アリル(46μL,0.54mmol)、炭酸セシウム(175mg,0.54mmol)およびN,N-ジメチルホルムアミド(5.0mL)の混合物を室温で1時間撹拌した。反応液を氷水(10mL)に注加し、ジエチルエーテルで抽出した。ジエチルエーテル層を飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥した。乾燥したろ過を濃縮し得られた淡黄色個体(78mg)に、濃塩酸(0.05mL)およびメタノール(1.5mL)を加え、50℃で3時間撹拌した。反応液を氷水(5mL)に注加し、ジクロロメタン/メタノールの混合溶液(5/1)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥した。乾燥したろ過を濃縮し得られた黄色固体をヘキサン/酢酸エチル(20/1)から再結晶し、標題化合物(30mg,0.10mmol,56%)を淡黄色固体として得た。
淡黄色固体:融点 207-208℃;IR(KBr):3410, 3275, 1608, 1562, 1493, 1464, 1282, 1149, 1092 cm-1; 1H-NMR (800 MHz, CD3OD) δ:4.67 (2H, td, J = 4.8, 1.8 Hz, OCH2CH=CH2), 5.30 (1H, ddd, J = 10.5, 3.2, 1.8 Hz, OCH2CH=CH2), 5.57 (1H, ddd, J = 17.2, 3.4, 1.8 Hz, OCH2CH=CH2), 6.12 (1H,tdd, J = 17.2, 10.5, 4.8 Hz, OCH2CH=CH2), 6.33 (1H, d, J = 2.1 Hz, H-2), 6.38 (1H, d, J = 2.1 Hz, H-4), 6.76 (1H, s), 7.47 (1H, s); 13C-NMR (200 MHz, CD3OD) δ:69.4 (OCH2CH=CH2), 95.0 (C-4), 96.3 (C-2), 101.7 (C-5), 105.4 (C-9a), 108.9 (C-8), 115.0 (C-8a), 116.5 (OCH2CH=CH2), 132.8 (OCH2CH=CH2), 143.2 (C-7), 150.6 (C-8b), 152.8 (C-6), 159.9 (C-4a), 161.0 (C-1), 163.5 (C-3), 175.7 (C-9) ; HRMS (ESI) m/z: [M-H]- Calcd for C16H11O6 300.0634; Found 300.0641.
比較例として、マンギフェリン8a(M8)を合成した。マンギフェリン8aは、以下のようにして合成した。1,3,2’,3’,4’,6,6’,7-オクタ-O-プロピオニルマンギフェリン(M7)(5.06g,5.68mmol)、酢酸アンモニウム(6.7g,87.0mmol)、メタノール(160mL)および水(20mL)の混合溶液を室温で6時間撹拌した。反応液から減圧濃縮によりメタノールを留去した後、残渣を酢酸エチル(100mL)で希釈した。その混合物を、水および飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー[CHCl3/CH3OH(20:1)]を用いて精製し、標題化合物(3.89g,95%)を淡黄色固体として得た。マンギフェリン8aは(a)式で表される。
IR (KBr): 3406, 1751, 1620, 1462, 1354, 1284, 1192, 1083 cm-1. 1H NMR (800 MHz, DMSO-d6, 25 ℃) δ: 0.74/0.94 (each 3H, t-like, J = 7.6, COCH2CH3), 0.97-1.02 (6H, m, COCH2CH3), 1.20/1.23 (each 1.5H, t-like, J = 7.6, COCH2CH3), 1.92-2.02 (2H, m, COCH2CH3), 2.15-2.33 (6H, m, COCH2CH3), 2.61-2.86 (2H, m, COCH2CH3), 3.85 (0.5H, dd-like, J = ca. 12.5, 1.9, H-6a’), 4.05 (0.5H, br d-like, J = ca. 12.5, H-6a’), 4.07 (0.5H, ddd, J = 9.8, 4.7, 1.9, H-5’), 4.09-4.14 (0.5H, m, H-6b’), 4.11 (0.5H, br d-like, J = ca. 9.5, H-5’), 4.24 (0.5H, dd, J = 12.5, 4.7, H-6b’), 4.96 (0.5H, d, J = 9.9, H-1’), 5.00 (0.5H, dd, J = 9.5, 9.5, H-4’), 5.02 (0.5H, dd, J = 9.8, 9.8, H-4’), 5.16 (0.5H, d, J = 10.0, H-1’), 5.35 (0.5H, dd, J = 9.5, 9.5, H-3’), 5.40 (0.5H, dd, J = 9.8, 9.5, H-3’), 5.49 (0.5H, dd, J = 10.0, 9.5, H-2’), 5.84 (0.5H, dd, J = 9.9, 9.5, H-2’), 6.72/6.75 (each 0.5H, s, H-4), 6.80/6.81 (each 0.5H, s, H-5), 7.29/7.30 (each 0.5H, s, H-8), 9.62/10.5 (each 1H, br s, OH), 11.2/11.4 (each 0.5H, br s, OH). 13C NMR (200 MHz, DMSO-d6, 25 ℃) δ: 8.81/8.86/8.96/9.02/9.06/9.11/9.12/9.20 (COCH2CH3), 26.6/26.89/26.91/26.94/27.00/27.04/27.1/27.4 (COCH2CH3), 62.1/62.3 (C-6’), 68.2/68.3 (C-4’), 68.7/70.4 (C-2’), 71.0/71.1 (C-1’), 73.8/74.1 (C-3’), 74.6/75.2 (C-5’), 99.5/100.8 (C-4), 102.5 (C-5), 106.6/107.8 (C-9a), 109.1 (C-8), 113.3 (C-2), 114.0/114.1 (C-8a), 143.8 (C-7), 149.77/149.82 (C-6, C-1), 151.3 (C-1), 153.3 (C-8b), 157.5/157.7 (C-4a), 160.7/162.2 (C-3), 171.1/171.9/172.2/172.5/172.8/173.1/173.4/173.6 (COCH2CH3) 172.68/172.71 (C-9). HRMS (ESI) m/z: [M-H]- Calcd for C34H37O16 701.2076; Found 701.2070.
他の比較例としてノラチリオールを用意した。
ノラチリオールを非特許文献48の方法に従って合成した。なお、ノラチリオールはCAS番号3542-72-1で表される既知物質であり、市販もされているので、購入してもよい。
(1)2,4,5-トリメトキシ安息香酸クロリド(化合物III)の製造方法
2,4,5-トリメトキシ安息香酸(化合物II、8.49g、0.040mol)にアルゴン雰囲気下、室温で塩化チオニル(5mL)を徐々に加えて溶解させたのち、6時間加熱還流を行った。反応終了後、反応混合物を減圧下留去し、2,4,5-トリメトキシ安息香酸クロリド(化合物III、8.30g、90%)を得た。得られた化合物(III)は、ただちに次の反応へ用いた。
上述のようにして得られた2,4,5-トリメトキシ安息香酸クロリド(化合物III、8.07g、0.035mol)、1,3,5-トリメトキシベンゼン(化合物IV、6.48g、0.0385mol)および無水ジエチルエーテル(500mL)の混合懸濁物にアルゴン雰囲気下、室温で塩化アルミニウム(16g)を徐々に加えた後、反応混合物を室温で48時間攪拌した。反応液を減圧下溶媒留去した後、残渣に水を加え、酢酸エチルにて抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=1:1,v/v)により精製し、2-ヒロドキシ-2’,4,4’,5,6’-ペンタメトキシベンゾフェノン(化合物V、8.43g、69%)を得た。
上述のようにして得られた2-ヒロドキシ-2’,4,4’,5,6’-ペンタメトキシベンゾフェノン(化合物V、6.97g、0.020mol)をピリジン(10mL)と水(10mL)との混合溶媒を溶かし、40%テトラブチルアンモニウムヒドロキシド水溶液(5mL)を加えて6時間加熱還流を行った。得られた反応混合物を5%塩酸に注加した後、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=1:1,v/v)により精製し、1,3,6,7-テトラメトキシキサントン(化合物VI、5.82g、92%)を得た。
上述のようにして得られた1,3,6,7-テトラメトキシキサントン(化合物VI、4.74g、0.015mol)とピリジン塩酸塩(5.00g)の混合物を6時間、200℃にて加熱攪拌した。得られた反応混合物を室温まで放冷後、5%塩酸に注加した後、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=7:1,v/v)により精製し、(2)式のノラチリオール(化合物I、2.65g、68%)を得た。ノラチリオール構造は(n)式で表される。
<実施例1:KMS-28BM細胞に対する各化合物の細胞死誘導効果の検討>
KMS-28BM細胞(骨髄腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。KMS-28BM細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図1に示す。
L363細胞(骨髄腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。L363細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図2に示す。
RPMI8226細胞(骨髄腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。RPMI8226細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図3に示す。
RPMI8226/B細胞(ボルテゾミブ耐性骨髄腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。RPMI8226/B細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図4に示す。
Rec-1(マントル細胞リンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。Rec-1細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図5に示す。
Raji細胞(バーキットリンパ腫)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。Raji細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図6に示す。
リンパ腫細胞株であるRaji細胞をリツキシマブ耐性に改変したものを作製し、RR1細胞と名付けた。
SU-DHL-4細胞(びまん性大細胞型B細胞リンパ腫)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。SU-DHL-4細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図9に示す。
CCRF-SB細胞(急性リンパ性白血病細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。CCRF-SB細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図10に示す。
MEC-1細胞(慢性リンパ性白血病細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。MEC-1細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図11に示す。
HUT-78細胞(末梢Tリンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。HUT-78細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図12に示す。
ATN-1細胞(成人T細胞白血病株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。ATN-1細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図13に示す。
RPMI1788細胞(ヒト正常B細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI-1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。RPMI1788細胞を96-well plateに播種後、各濃度の化合物を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図14に示す。
KMS-28BM細胞を用いて各化合物投与によるNIK阻害作用およびNIKの下流シグナルであるIKK、NF-κB p52、NF-κB p65の活性化動態について、イムノブロテッィングで検討した結果、NIK活性化阻害、IKKの活性阻害、NF-κB p52およびNF-κB p65の核移行阻害を認めた(図15、図16)。
KMS-28BM細胞を用いて各化合物投与によるCD138発現抑制作用について、Flow cytometryで検討した結果、CD138発現抑制作用を認めた。
KMS-28BM細胞を用いて各化合物投与によるCD20発現増加作用について、Flow cytometryで検討した結果、CD20発現増加作用を認めた。
L363細胞を用いて各化合物投与によるCD138発現抑制作用について、Flow cytometryで検討した結果、CD138発現抑制作用を認めた。
L363細胞を用いて各化合物投与によるCD20発現増加作用について、Flow cytometryで検討した結果、CD20発現増加作用を認めた。
KMS-28BM細胞を用いて各化合物投与によりCD20発現増加を誘導後、抗CD20モノクローナル抗体であるリツキシマブでの細胞死誘導効果を検討した結果、各化合物とリツキシマブ併用による殺細胞作用認めた。
L363細胞を用いて各化合物投与によりCD20発現増加を誘導後、抗CD20モノクローナル抗体であるリツキシマブでの細胞死誘導効果を検討した結果、各化合物とリツキシマブ併用による殺細胞作用認めた。
KMS-28BM細胞を用いて各化合物投与によるIgG分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、IgG分泌抑制作用を認めた。
KMS-28BM細胞を用いて各化合物投与による免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用を認めた。
KMS-28BM細胞を用いて各化合物投与によるIL-6の分泌抑制作用について、Luminexで検討した結果、IL-6の分泌抑制作用を認めた。
L363細胞を用いて各化合物投与によるIgG分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、IgG分泌抑制作用を認めた。
L363細胞を用いて各化合物投与による免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用を認めた。
L363細胞を用いて各化合物投与によるMIP-1αの分泌抑制作用について、Luminexで検討した結果、MIP-1αの分泌抑制作用を認めた。
L363細胞をNOD/ShiJic-scidJclマウスに移植し、M9を経口投与した場合の腫瘍増殖抑制作用について検討した結果、顕著な腫瘍増殖抑制作用を認めた。
以上のように、M9投与群は顕著に腫瘍増殖を抑制することが分かった。
Raji細胞をNOD/ShiJic-scidJclマウスに移植し、M9およびM14を経口投与した場合の腫瘍増殖抑制作用について検討した結果、顕著な腫瘍増殖抑制作用を認めた。
Claims (21)
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含む悪性腫瘍疾患を改善する医薬組成物。
- 前記悪性腫瘍疾患は、多発性骨髄腫、リンパ性白血病、悪性リンパ腫(MALTリンパ腫、DLBCL、マントル細胞リンパ腫、バーキットリンパ腫、ホジキンリンパ腫、成人T細胞白血病、末梢Tリンパ腫等)、膵癌、乳癌、悪性黒色腫、肺癌、肝癌、胃癌、大腸癌、頭頸部腫瘍、グリオーマ、腎癌、卵巣癌および子宮体癌等の少なくとも1種であることを特徴とする請求項2に記載された悪性腫瘍疾患を改善する医薬組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含むボルテゾミブ耐性多発性骨髄腫またはリツキシマブ耐性悪性リンパ腫を改善する医薬組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含む多発性骨髄腫の随伴症状であるCRAB等を改善する医薬組成物。
- 前記CRAB等は、高カルシウム血症、腎障害、貧血、骨病変、アミロイドーシス、過粘稠度症候群の少なくとも1種であることを特徴とする請求項5に記載されたCRAB等を改善する医薬組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物と、CD20モノクローナル抗体医薬品を有効成分に含む多発性骨髄腫を改善する医薬組成物。
- 前記CD20モノクローナル抗体医薬品が、リツキシマブ、オビヌツズマブ、オファツズマブ、イブリツモマブ チウキセタン等の少なくとも1種であることを特徴とする請求項7に記載された多発性骨髄腫を改善する医薬組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含む多発性骨髄腫細胞のB細胞様へ転換誘導する医薬組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含むIL-6およびMIP-1αオートクラインによる細胞増殖を抑制する医薬組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含む悪性腫瘍細胞の増殖を阻害する増殖阻害用組成物。
- 前記悪性腫瘍細胞は、多発性骨髄腫、リンパ性白血病、悪性リンパ腫(MALTリンパ腫、DLBCL、マントル細胞リンパ腫、バーキットリンパ腫、ホジキンリンパ腫、成人T細胞白血病、末梢Tリンパ腫等)、膵癌、乳癌、悪性黒色腫、肺癌、肝癌、胃癌、大腸癌、頭頸部腫瘍、グリオーマ、腎癌、卵巣癌および子宮体癌等の少なくとも1種の細胞であることを特徴とする請求項11に記載された増殖阻害用組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含むボルテゾミブ耐性多発性骨髄腫およびリツキシマブ耐性悪性リンパ腫の増殖を阻害する増殖阻害用組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含む多発性骨髄腫細胞のB細胞様へ転換誘導する組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含む多発性骨髄腫のIL-6およびMIP-1αオートクラインによる細胞増殖を阻害する増殖阻害用組成物。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を含む加工食品。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含み、多発性骨髄腫、リンパ性白血病、悪性リンパ腫(MALTリンパ腫、DLBCL、マントル細胞リンパ腫、バーキットリンパ腫、ホジキンリンパ腫、成人T細胞白血病、末梢Tリンパ腫等)、膵癌、乳癌、悪性黒色腫、肺癌、肝癌、胃癌、大腸癌、頭頸部腫瘍、グリオーマ、腎癌、卵巣癌および子宮体癌等の悪性腫瘍およびボルテゾミブ耐性多発性骨髄腫およびリツキシマブ耐性悪性リンパ腫の症状改善用である旨の表示のある加工食品。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含み、多発性骨髄腫に伴い発症するCRAB等の症状改善用である旨の表示のある加工食品。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を含む剤。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含み、多発性骨髄腫、リンパ性白血病、悪性リンパ腫(MALTリンパ腫、DLBCL、マントル細胞リンパ腫、バーキットリンパ腫、ホジキンリンパ腫、成人T細胞白血病、末梢Tリンパ腫等)、膵癌、乳癌、悪性黒色腫、肺癌、肝癌、胃癌、大腸癌、頭頸部腫瘍、グリオーマ、腎癌、卵巣癌および子宮体癌等の悪性腫瘍およびボルテゾミブ耐性多発性骨髄腫およびリツキシマブ耐性悪性リンパ腫の症状改善用である旨の表示のある剤。
- 請求項1に記載された(1)~(12)式の少なくとも1種の化合物を有効成分に含み、多発性骨髄腫に伴い発症するCRAB等の症状改善用である旨の表示のある剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21910875.0A EP4253372A1 (en) | 2020-12-22 | 2021-12-22 | Pharmaceutical composition for ameliorating malignant diseases |
JP2022571562A JPWO2022138735A1 (ja) | 2020-12-22 | 2021-12-22 | |
US18/268,434 US20240124430A1 (en) | 2020-12-22 | 2021-12-22 | Pharmaceutical composition for ameliorating malignant diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-212015 | 2020-12-22 | ||
JP2020212015 | 2020-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022138735A1 true WO2022138735A1 (ja) | 2022-06-30 |
Family
ID=82157025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/047614 WO2022138735A1 (ja) | 2020-12-22 | 2021-12-22 | 悪性腫瘍疾患の改善用医薬組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240124430A1 (ja) |
EP (1) | EP4253372A1 (ja) |
JP (1) | JPWO2022138735A1 (ja) |
WO (1) | WO2022138735A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023234312A1 (ja) * | 2022-05-30 | 2023-12-07 | 学校法人近畿大学 | 自己免疫系疾患の改善用医薬組成物 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04368379A (ja) * | 1991-06-13 | 1992-12-21 | Natl Sci Council | キサントン誘導体又はそのエステルを有効成分とする血栓予防治療剤 |
JPH0782263A (ja) | 1993-09-14 | 1995-03-28 | Natl Sci Council | 新規キサントン化合物 |
CN102432601A (zh) * | 2011-10-24 | 2012-05-02 | 广西中医学院 | 一种芒果苷五乙酯化衍生物 |
CN102432602A (zh) * | 2011-10-24 | 2012-05-02 | 广西中医学院 | 芒果苷七丙酯化衍生物 |
CN103755692A (zh) * | 2014-01-29 | 2014-04-30 | 昆明制药集团股份有限公司 | 一种化合物及其制备方法、用途、药物组合物与制剂 |
CN104257650A (zh) * | 2014-09-12 | 2015-01-07 | 广西中医药大学 | 一种药物制剂 |
CN104873487A (zh) * | 2015-05-29 | 2015-09-02 | 广西中医药大学 | 一种具有抗肝纤维化作用的药物 |
CN104887660A (zh) * | 2015-05-29 | 2015-09-09 | 广西中医药大学 | 一种降血脂药物 |
JP2016531858A (ja) | 2013-09-26 | 2016-10-13 | ヤンセン ファーマシューティカ エヌ.ベー. | 新規な、NIK阻害剤としての3−(1H−ピラゾール−4−イル)−1H−ピロロ[2,3−c]ピリジン誘導体 |
JP2017031146A (ja) | 2015-07-30 | 2017-02-09 | 学校法人近畿大学 | Nik阻害剤 |
WO2020130102A1 (ja) * | 2018-12-19 | 2020-06-25 | 学校法人近畿大学 | 自己免疫疾患の改善用組成物 |
WO2020162638A1 (ja) * | 2019-02-08 | 2020-08-13 | 学校法人近畿大学 | 悪性腫瘍疾患の改善用組成物 |
-
2021
- 2021-12-22 JP JP2022571562A patent/JPWO2022138735A1/ja active Pending
- 2021-12-22 US US18/268,434 patent/US20240124430A1/en active Pending
- 2021-12-22 WO PCT/JP2021/047614 patent/WO2022138735A1/ja active Application Filing
- 2021-12-22 EP EP21910875.0A patent/EP4253372A1/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04368379A (ja) * | 1991-06-13 | 1992-12-21 | Natl Sci Council | キサントン誘導体又はそのエステルを有効成分とする血栓予防治療剤 |
JPH0782263A (ja) | 1993-09-14 | 1995-03-28 | Natl Sci Council | 新規キサントン化合物 |
CN102432601A (zh) * | 2011-10-24 | 2012-05-02 | 广西中医学院 | 一种芒果苷五乙酯化衍生物 |
CN102432602A (zh) * | 2011-10-24 | 2012-05-02 | 广西中医学院 | 芒果苷七丙酯化衍生物 |
JP2016531858A (ja) | 2013-09-26 | 2016-10-13 | ヤンセン ファーマシューティカ エヌ.ベー. | 新規な、NIK阻害剤としての3−(1H−ピラゾール−4−イル)−1H−ピロロ[2,3−c]ピリジン誘導体 |
CN103755692A (zh) * | 2014-01-29 | 2014-04-30 | 昆明制药集团股份有限公司 | 一种化合物及其制备方法、用途、药物组合物与制剂 |
CN104257650A (zh) * | 2014-09-12 | 2015-01-07 | 广西中医药大学 | 一种药物制剂 |
CN104873487A (zh) * | 2015-05-29 | 2015-09-02 | 广西中医药大学 | 一种具有抗肝纤维化作用的药物 |
CN104887660A (zh) * | 2015-05-29 | 2015-09-09 | 广西中医药大学 | 一种降血脂药物 |
JP2017031146A (ja) | 2015-07-30 | 2017-02-09 | 学校法人近畿大学 | Nik阻害剤 |
WO2020130102A1 (ja) * | 2018-12-19 | 2020-06-25 | 学校法人近畿大学 | 自己免疫疾患の改善用組成物 |
WO2020162638A1 (ja) * | 2019-02-08 | 2020-08-13 | 学校法人近畿大学 | 悪性腫瘍疾患の改善用組成物 |
Non-Patent Citations (51)
Title |
---|
AHSANA DAR, SHAHEEN FAIZI, SABIRA NAQVI, TALAT ROOME, SADIA ZIKR-UR-REHMAN, MUHAMMAD ALI, SADIQA FIRDOUS, SYED TARIQUE MOIN: "Analgesic and Antioxidant Activity of Mangiferin and Its Derivatives: the Structure Activity Relationship", BIOLOGICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, vol. 28, no. 4, 1 April 2005 (2005-04-01), pages 596 - 600, XP055089549, ISSN: 09186158, DOI: 10.1248/bpb.28.596 * |
ALLEN ICWILSON JEARTHUR JCWOODFORD RMDAVIS BKURONIS JMHERFARTH HHJOBIN CROGERS ABTING JP, IMMUNITY, vol. 36, 2012, pages 742 - 754 |
ANNUNZIATA CMDAVIS REDEMCHENKO YBELLAMY WGABREA AZHAN FLENZ GHANAMURA IWRIGHT GXIAO W, CANCER CELL, vol. 12, 2007, pages 115 - 130 |
CAS , no. 3542-72-1 |
CHERECHES GBARBOS OBUIGA RBALACESCU OIANCU DTODOR NBALACESCU LMIRON NBEJINARIU NCIULEANU TE, J. BUON, vol. 22, 2017, pages 658 - 666 |
CHERRY EMLEE DWJUNG JUSITCHERAN R, MOL CANCER, vol. 14, 27 January 2015 (2015-01-27), pages 9 |
DAS RCOUPAR JCLAVIJO PESALEH ACHENG TFYANG XCHEN JVAN WAES CCHEN Z, MOL CARCINOG, vol. 58, 2019, pages 411 - 425 |
DEMCHENKO YNGLEBOV OKZINGONE AKEATS JJBERGSAGEL PLKUEHL WM, BLOOD, vol. 115, 2010, pages 3541 - 3552 |
DIAZ, J.G. ; DE PAZ, P.P. ; HERZ, W.: "New water soluble flavone and xanthone glycosides from Hypericum canariense L.", PHYTOCHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 4, 17 December 2010 (2010-12-17), AMSTERDAM, NL , pages 171 - 175, XP027516319, ISSN: 1874-3900, DOI: 10.1016/j.phytol.2010.05.002 * |
FEIGE MHVIETH MSOKOLOVA OTAGER CNAUMANN M, BIOCHIM BIOPHYS ACTA MOL CELL RES, vol. 1865, 2018, pages 545 - 550 |
FRASSANITO MACUSMAI AIODIC E GDAMMACCO F: "Autocrine interleukin -6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis", BLOOD, vol. 97, 2001, pages 483 - 489 |
HARMER DFALANK CREAGAN MR, FRONT. ENDOCRINOL., vol. 9, 2019, pages 788 |
HE BCHADBURN AJOU ESCHATTNER EJKNOWLES DMCERUTTI A, J IMMUNOL, vol. 172, 2004, pages 3268 - 3279 |
HU LWU WCHAI XLUO JWU Q, BIOORG. MED. CHEM. LETT., vol. 21, 2011, pages 4013 - 4015 |
JABLONSKA EDAKOWICZ LRATAJCZAK-WRONA WGARLEY MSAWICKA-POWIERZA JKRAWCZUK-RYBAK M, CLIN LAB, vol. 60, 2014, pages 1757 - 1764 |
JIANG MLIN JXING HAN JYANG JWANG BYU MZHU Y, PEER J, vol. 8, 2020, pages e9453 |
KERN CCORNUEL JFBILLARD CTANG RROUILLARD DSTENOU VDEFRANCE TAJCHENBAUM-CYMBALISTA FSIMONIN PYFELDBLUM S, BLOOD, vol. 103, no. 4, 2004, pages 2247 - 2253 |
KHLAIPHUENGSIN ACHUAYPEN NPINJAROEN NSIRICHINDAKUL BHIRANKARN NTANGKIJVANICH P: "Plasma B-cell activating factor levels and polymorphisms in hepatitis B-related hepatocellular carcinoma: clinical correlation and prognosis", ASIAN PAC J ALLERGY IMMUNOL, 2020 |
KOIZUMI MHIASA YKUMAGI TYAMANISHI HAZEMOTO NKOBATA TMATSUURA BABE MONJI M, PLOS ONE, vol. 8, 2013, pages e71367 |
LEE OLHORVATH NLEE CJOSHUA DHO JSZER JQUACH HSPENCER AHARRISON SMOLLEE P, INTERN. MED. J., vol. 47, 2017, pages 938 - 951 |
LI, XUE-JIAN; DU, ZHENG-CAI; DENG, JIA-GANG; HUANG, YAN; LIU, BU-MING; HU, WEN-JI; LU, WEN-JIE: "Synthesis and anti-inflammatory activity of Mangiferin acylated-derivatives", CHINESE JOURNAL OF EXPERIMENTAL TRADITIONAL MEDICAL FORMULAE, vol. 18, no. 24, 1 January 2012 (2012-01-01), CN , pages 228 - 232, XP009537679, ISSN: 1005-9903, DOI: 10.13422/j.cnki.syfjx.2012.24.046 * |
LUA JQAYYUM TEDWARDS JROSEWEIR AK, UROL INT, vol. 101, 2018, pages 190 - 196 |
MAEDA SYOSHIDA HOGURA KMITSUNO YHIRATA YYAMAJI YAKANUMA MSHIRATORI YOMATA M, GASTROENTEROLOGY, vol. 119, 2000, pages 97 - 108 |
MAIA SPELLETIER MDING JHSU YMSALLAN SERAO SPNADLER LMCARDOSO AA, PLOS ONE, vol. 6, 2011, pages e20787 |
MCCARTHY BAYANG LDING JREN MKING WELSALANTY MZAKHARY ISHARAWY MCUI HDING HF, BMC CANCER, vol. 12, 2012, pages 203 |
MOORE PABELVEDERE 0ORR APIERI KLAFLEUR DWFENG PSOPPET DCHARTERS MGENTZ RPARMELEE D, SCIENCE, vol. 285, 1999, pages 260 - 263 |
NISHINA TYAMAGUCHI NGOHDA JSEMBA KINOUE J, BIOCHEM BIOPHYS RES COMMUN, vol. 388, 2009, pages 96 - 101 |
ODQVIST LSANCHEZ-BEATO MMONTES-MORENO SMARTIN-SANCHEZ EPAJARES RSANCHEZ-VERDE LORTIZ-ROMERO PLRODRIGUEZ JRODRIGUEZ-PINILLA SMINIES, CLIN CANCER RES, vol. 19, 2013, pages 2319 - 2330 |
OKI YGEORGAKIS GVMIGONE TSKWAK LWYOUNES A, HAEMATOLOGICA, vol. 92, 2007, pages 269 - 270 |
PELEKANOU VNOTAS GATHANASOULI PALEXAKIS KKIAGIADAKI FPEROULIS NKALYVIANAKI KKAMPOURI EPOLIOUDAKI HTHEODOROPOULOS P, FRONT. ONCOL., vol. 8, 2018, pages 301 |
PHAM LVFU LTAMAYO ATBUESO-RAMOS CDRAKOS EVEGA FMEDEIROS LJFORD RJ, BLOOD, vol. 117, 2011, pages 200 - 210 |
RAJKUMAR SVDIMOPOULOS MAPALUMBO ABLADE JMERLINI GMATEOS MVKUMAR SHILLENGASS JKASTRITIS ERICHARDSON P, LANCET ONCOL, vol. 15, 2014, pages e538 - 48 |
RANUNCOLO SMPITTALUGA SEVBUOMWAN MOJAFFE ESLEWIS BA, BLOOD, vol. 120, 2012, pages 3756 - 3763 |
RIHACEK MBIENERTOVA-VASKU JVALIK DSTERBA JPILATOVA KZDRAZILOVA-DUBSKA L, BIOMED. RES. INT., vol. 2015, 2015, pages 792187 |
ROSEBECK SMADDEN LJIN XGU SAPEL IJAPPERT AHAMOUDI RANOELS HSAGAERT XVAN LOO P, SCIENCE, vol. 331, 2011, pages 468 - 472 |
ROUSSOU MTASIDOU ADIMOPOULOS MAKASTRITIS EMIGKOU MCHRISTOULAS DGAVRIATOPOULOU MZAGOURI FMATSOUKA CANAGNOSTOU D, LEUKEMIA, vol. 23, 2009, pages 2177 - 2181 |
SAITOH YMARTINEZ BRUYN VJUOTA SHASEGAWA AYAMAMOTO NIMOTO IINAZAWA JYAMAOKA S, LUNG CANCER, vol. 70, 2010, pages 263 - 270 |
SAITOH YYAMAMOTO NDEWAN MZSUGIMOTO HMARTINEZ BRUYN VJIWASAKI YMATSUBARA KQI XSAITOH TIMOTO I, BLOOD, vol. 111, 2008, pages 5118 - 5129 |
SHI WYE ZZHUANG LLI YSHUAI WZUO ZMAO XLIU RWU JCHEN S, J PATHOL, vol. 240, 2016, pages 352 - 365 |
SUN BLI LXU MWANG XWANG FNI H, J. PEDIATR. HEMATOL. ONCOL., vol. 38, 2016, pages 167 - 172 |
SUTHERLAND APMACKAY FMACKAY CR, PHARMACOL THER, vol. 112, 2006, pages 774 - 786 |
TERPOS EPOLITOU MVINIOU NRAHEMTULLA A, SIGNIFICANCE OF LEUK LYMPHOMA, vol. 46, 2005, pages 1699 - 1707 |
THU YMRICHMOND A, CYTOKINE GROWTH FACTOR REV, vol. 21, 2010, pages 213 - 226 |
THU YMSU YYANG JSPLITTGERBER RNA SBOYD AMOSSE CSIMONS CRICHMOND A, ONCOGENE, vol. 31, 2012, pages 3607 - 3620 |
TSUBAKI MKATO CISONO AKANEKO JISOZAKI MSATOU TITOH TKIDERA YTANIMORI YYANAE M, J. CELL. BIOCHEM., vol. 111, 2010, pages 1661 - 1672 |
UNO MSAITOH YMOCHIDA KTSURUYAMA EKIYONO TIMOTO IINAZAWA JYUASA YKUBOTA TYAMAOKA S, PLOS ONE, vol. 9, 2014, pages e88347 |
VRABEL DPOUR LSEVCIKOV S, BLOOD REV, vol. 34, 2019, pages 56 - 66 |
XIE CQUAN RWANG LCHEN CYAN WFU Y, CLIN. EXP., vol. 198, 2019, pages 131 - 140 |
YAMAMOTO MITO TSHIMIZU TISHIDA TSEMBA KWATANABE SYAMAGUCHI NINOUE J, CANCER SCI, vol. 101, 2010, pages 2391 - 2397 |
ZHOU XLI HCHAI YLIU Z, INT J GYNECOL CANCER, vol. 25, 2015, pages 770 - 778 |
ZHU JSUN LLIN SZHAO RZHOU LFANG DCHEN LLIU JSHI WZHANG L, J. EXP. CLIN. CANCER RES., vol. 31, 2012, pages 31 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023234312A1 (ja) * | 2022-05-30 | 2023-12-07 | 学校法人近畿大学 | 自己免疫系疾患の改善用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP4253372A1 (en) | 2023-10-04 |
JPWO2022138735A1 (ja) | 2022-06-30 |
US20240124430A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020162638A1 (ja) | 悪性腫瘍疾患の改善用組成物 | |
US9604973B2 (en) | Anti-cancer polyketide compounds | |
CN101012211B (zh) | 取代的穿心莲内酯衍生物、制备方法及其药物组合物 | |
WO2022138735A1 (ja) | 悪性腫瘍疾患の改善用医薬組成物 | |
KR101674145B1 (ko) | 데쿠르시놀 카바메이트 유도체, 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
JP2019523230A (ja) | 抗転移性2H‐セレノフェノ[3,2‐h]クロメン、それらの合成、および同薬剤の使用方法 | |
JP2006273741A (ja) | PPARγリガンド活性を有する組成物 | |
KR20170129688A (ko) | 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도 | |
JPWO2005074906A1 (ja) | 治療剤 | |
KR101669759B1 (ko) | 히드록시벤질리덴 크로마논계 화합물을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 | |
JP2009126852A (ja) | ピリミジン誘導体を有効成分として含有する医薬組成物 | |
CN112513000A (zh) | 新型联苯衍生物化合物及其用途 | |
JP4993969B2 (ja) | 抗発癌プロモーター活性剤 | |
GB2579480A (en) | Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient | |
US20240115589A1 (en) | Pharmaceutical composition for preventing cytokine storm | |
JP7223477B2 (ja) | Trpv4活性抑制剤 | |
US20220110962A1 (en) | Analogues of oleuropein and oleacein and uses thereof | |
WO2020203593A1 (ja) | 免疫賦活剤及び免疫賦活用飲食品 | |
US20230372375A1 (en) | Sglt-2 inhibitor sarcosine co-crystal, preparation method therefor and use thereof | |
JP7496123B2 (ja) | ミトコンドリアフェリチン発現誘導剤 | |
JP7193150B2 (ja) | 新規化合物 | |
WO2022045041A1 (ja) | チオレドキシン相互作用タンパク質発現抑制剤 | |
WO2023204271A1 (ja) | 抗SARS-CoV-2剤及び化合物の使用 | |
KR102100729B1 (ko) | 안트라퀴논계 화합물 및 이를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 | |
CN115304513A (zh) | 具有抗炎活性的查尔酮类衍生物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21910875 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022571562 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18268434 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2021910875 Country of ref document: EP Effective date: 20230628 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |